

## 6.2 Parent company financial statements

### 6.2.1 Parent company financial statements of bioMérieux SA for the fiscal years ended December 31, 2024 and 2025

#### Balance sheet

##### Assets

In millions of euros	12/31/2025			12/31/2024
	Gross	Depreciation, amortization and impairment	Net	Net
<b>Intangible assets</b>				
Development expenses	14.2	-14.2	-	-
Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets	278.2	-131.2	147.0	32.4
Goodwill	131.9	-	131.9	131.9
Other intangible assets	5.4	-4.7	0.7	1.1
Intangible assets under construction, advances and deposits	2.1	-	2.1	2.6
<b>Property, plant and equipment</b>				
Land	23.5	-1.6	21.9	20.6
Buildings	365.4	-231.4	134.0	137.7
Technical installations, industrial equipment and tools	403.8	-272.0	131.8	134.1
Other property, plant and equipment	70.8	-58.0	12.8	14.5
Property, plant and equipment under construction, advances, and deposits.	125.1	-	125.1	66.6
<b>Non-current financial assets <sup>(a)</sup></b>				
Equity investments	1,354.5	-163.1	1,191.4	1,042.0
Receivables from equity investments	5.2	-	5.2	5.1
Other financial assets	188.3	-78.7	109.6	123.8
Other non-current financial assets	0.6	-	0.6	0.6
<b>Total non-current assets (I)</b>	<b>2,969.1</b>	<b>-954.8</b>	<b>2,014.2</b>	<b>1,712.9</b>
<b>Inventories and work-in-progress</b>				
Raw materials and other supplies	45.3	-2.8	42.4	45.7
Work-in-progress	30.2	-0.8	29.4	32.5
Finished products	41.6	-1.4	40.2	38.4
Goods held for sale	136.8	-5.6	131.2	117.6
Advances and deposits on orders	14.8	-	14.8	8.9
<b>Receivables <sup>(b)</sup></b>				
Trade receivables	574.1	-13.8	560.3	514.9
Other receivables	91.1	-	91.1	75.5
Prepaid expenses	21.7	-	21.7	16.4
<b>Investment securities</b>				
Treasury shares	35.5	-	35.5	39.1
Other securities	178.1	-	178.1	133.8
Forward financial instruments and tokens held	1.3	-	1.3	3.0
Cash and cash pooling	409.2	-1.6	407.6	702.5
<b>Total current assets (II)</b>	<b>1,579.6</b>	<b>-26.1</b>	<b>1,553.5</b>	<b>1,728.3</b>
Loan issue costs (III)	0.2	-	0.2	0.3
Translation and valuation differences - Assets (IV)	2.1	-	2.1	9.1
<b>TOTAL ASSETS (I + II + III + IV)</b>	<b>4,551.0</b>	<b>-980.9</b>	<b>3,570.1</b>	<b>3,450.6</b>
(a) Of which due in less than one year	0.2	-	0.2	0.2
(b) Of which due in less than one year	619.0	-13.8	605.2	537.1

## Shareholders' equity and liabilities

<i>In millions of euros</i>	<b>12/31/2025</b>	<b>12/31/2024</b>
Share capital	12.0	12.0
Share, merger and acquisition premiums	74.4	74.4
<b>Reserves</b>		
Legal reserve	1.2	1.2
Reserves required by the articles of association	905.0	895.0
Regulatory reserves	1.0	1.0
Retained earnings	635.9	300.1
Net income for the year (profit or loss)	320.5	451.9
Capital expenditure subsidies	0.2	0.1
Statutory provisions	84.1	84.1
<b>Total equity (I)</b>	<b>2,034.3</b>	<b>1,819.9</b>
Provisions for risks	2.9	12.6
Provisions for charges	73.8	68.5
<b>Total provisions (II)</b>	<b>76.6</b>	<b>81.1</b>
Other bond issues	201.6	201.6
Borrowings and debts from credit institutions	0.1	0.1
Miscellaneous borrowings and financial debt	630.2	726.3
Forward financial instruments	1.5	0.5
Trade payables	327.4	334.7
Tax and social-security debts	247.6	237.6
Debts on fixed assets and related accounts	31.1	27.2
Other payables	14.0	16.3
Deferred income	4.5	4.6
<b>Total debts <sup>(a)</sup> (III)</b>	<b>1,458.0</b>	<b>1,549.1</b>
Translation and valuation differences - Liabilities (IV)	1.2	0.5
<b>TOTAL LIABILITIES (I + II + III + IV)</b>	<b>3,570.1</b>	<b>3,450.6</b>
(a) <i>Of which due in less than one year</i>	1,158.6	1,263.1

## Profit & loss statement

<i>In millions of euros</i>	2025	2024
<b>Operating income</b>		
Sales of goods	723.7	672.8
Production sold	970.5	967.9
<b>Net amount of sales</b>	<b>1,694.2</b>	<b>1,640.7</b>
Stored production	-2.3	-1.5
Capitalized production	10.1	9.4
Subsidies	1.1	2.1
Reversals of amortization, impairment and provisions	45.2	28.9
Proceeds from disposals of property, plant and equipment and intangible assets	2.0	-
Other income	0.9	0.1
<b>Total operating income (I)</b>	<b>1,751.2</b>	<b>1,679.6</b>
<b>Operating expenses</b>		
Purchases of goods	-525.6	-488.0
Change in inventories	13.9	-20.3
Purchases of raw materials and other supplies	-130.5	-130.4
Change in raw material inventories	-3.0	-5.6
Other purchases and external expenses <sup>(a)</sup>	-491.4	-469.5
Taxes, duties and similar taxes	-20.3	-18.9
Wages and salaries	-327.1	-311.1
Social security contributions	-134.3	-128.9
<b>Amortization and impairment expenses:</b>		
On fixed assets: amortization expenses	-64.0	-60.7
On fixed assets: impairment expenses	-0.9	-0.0
On current assets: impairment expenses	-12.3	-12.9
Provisions	-4.6	-28.2
Carrying amounts of sold intangible assets and property, plant and equipment	-12.0	-
Other expenses	-30.1	-18.8
<b>Total operating expenses (II)</b>	<b>-1,742.1</b>	<b>-1,693.4</b>
<b>1. OPERATING INCOME (I - II)</b>	<b>9.1</b>	<b>-13.8</b>
<i>(a) including property leasing agreement expenses</i>	-4.1	-4.5

<i>In millions of euros</i>	2025	2024
<b>Financial income</b>		
From participating interests <sup>(b)</sup>	349.9	480.3
From other securities and receivables from non-current assets <sup>(b)</sup>	14.7	21.7
Other interest and similar income <sup>(b)</sup>	8.5	6.1
Reversal of impairment and provisions	7.8	17.0
Foreign exchange gains	115.9	100.4
Income from sales of non-current financial assets	0.0	-
Net proceeds from the sale of investment securities and cash instruments.	3.6	4.7
<b>Total financial income (III)</b>	<b>500.4</b>	<b>630.3</b>
<b>Financial expenses</b>		
Amortization and impairment expenses and provisions	-61.9	-42.2
Interest and similar expenses <sup>(c)</sup>	-26.4	-32.2
Foreign exchange losses	-111.9	-103.1
Book value of sold non-current financial assets	-	-
Net expenses from the sale of investment securities and cash instruments.	-0.7	-0.7
<b>Total financial expenses (IV)</b>	<b>-200.9</b>	<b>-178.2</b>
<b>2. FINANCIAL INCOME (III - IV)</b>	<b>299.6</b>	<b>452.0</b>
<b>3. NET INCOME BEFORE NON-RECURRING ITEMS AND TAX (I - II + III - IV)</b>	<b>308.7</b>	<b>438.3</b>
Non-recurring income (V)	14.0	31.9
Non-recurring expenses (VI)	-14.0	-35.0
<b>4. NON-RECURRING INCOME (V - VI)</b>	<b>-0.0</b>	<b>-3.1</b>
Income taxes (VII)	11.9	16.7
<b>Total income (I + III + V)</b>	<b>2,265.6</b>	<b>2,341.8</b>
<b>Total expenses (II + IV + VI + VII)</b>	<b>-1,945.1</b>	<b>-1,889.9</b>
<b>PROFIT OR LOSS</b>	<b>320.5</b>	<b>451.9</b>
<i>(b) including income from related parties</i>	14.7	21.7
<i>(c) including interests in related parties</i>	-22.2	-27.4

## 6.2.2 Notes to the Financial Statements

bioMérieux is a French joint stock company (société anonyme) with a Board of Directors, governed by the French Commercial Code (Code de commerce) and all other applicable laws and regulations, registered with the Lyon Trade and Companies

Register under number 673 620 399. The Company has been established in France since its incorporation.

The Company's headquarters are located in Marcy l'Étoile (69280), France.

### CONTENTS

<b>NOTE 1</b>	General accounting principles	328	<b>NOTE 13</b>	Trade and other operating payables	348
<b>NOTE 2</b>	Information about the entity that prepares the consolidated financial statements	330	<b>NOTE 14</b>	Debt schedule	349
<b>NOTE 3</b>	Significant events of the fiscal year	330	<b>NOTE 15</b>	Accrued expenses and income	349
<b>NOTE 4</b>	Non-current assets	331	<b>NOTE 16</b>	Sales	349
<b>NOTE 5</b>	Inventories	341	<b>NOTE 17</b>	Research & Development expenses	350
<b>NOTE 6</b>	Trade and other receivables from current assets	341	<b>NOTE 18</b>	Personnel costs	350
<b>NOTE 7</b>	Due dates of receivables	342	<b>NOTE 19</b>	Net financial income	351
<b>NOTE 8</b>	Cash and cash equivalents and investment securities	342	<b>NOTE 20</b>	Non-recurring income	352
<b>NOTE 9</b>	Translation differences	343	<b>NOTE 21</b>	Corporate income tax	352
<b>NOTE 10</b>	Equity and free shares grant plans	343	<b>NOTE 22</b>	Hedging instruments	353
<b>NOTE 11</b>	Provisions for financial risks and losses	345	<b>NOTE 23</b>	Off-balance sheet commitments	354
<b>NOTE 12</b>	Net debt	346	<b>NOTE 24</b>	Related parties	355
			<b>NOTE 25</b>	Statutory Auditors' fees	356

## NOTE 1 General accounting principles

The accounts have been prepared in accordance with Regulations 2014-03 of the French accounting standards authority (Autorité des normes comptables – ANC) updated to Regulation 2022-06 on the Modernization of Financial Statements (French general accounting plans – PCG).

At December 31, 2025, the Company applied the new ANC Regulation 2022-06 on the general accounting plan for the first year. In particular, this regulation removes the “expense transfer” accounts and introduces a new, more restrictive definition of non-recurring income.

Non-recurring income now includes:

- income and expenses directly related to a major and extraordinary event;

This change in accounting regulations has no impact on the balance sheet at the beginning of the fiscal year. It impacts the presentation of the 2025 profit & loss statement as follows:

In millions of euros	Impact on 2025	Reclassifications of non-recurring income			
		Free share grant	Capital gains and losses on the disposal of fixed assets	Other reclassifications	Discontinuation of expense transfers
Total operating income	6.2	-1.7	12.0	0.0	-4.2
Total operating expenses	-9.6	-1.7	-12.0	-0.1	4.2
<b>1. Operating income</b>	<b>-3.5</b>	<b>-3.4</b>	<b>0.0</b>	<b>-0.1</b>	<b>-</b>
<b>2. Net financial income</b>	<b>0.0</b>	<b>-</b>	<b>0.0</b>	<b>-</b>	<b>-</b>
<b>3. Net income before non-recurring items and tax</b>	<b>-3.5</b>	<b>-3.4</b>	<b>0.0</b>	<b>-0.1</b>	<b>-</b>
Non-recurring income	-32.9	-20.9	-12.0	-0.0	-
Non-recurring expenses	36.4	24.3	12.0	0.1	-
<b>4. Non-recurring income</b>	<b>3.5</b>	<b>3.4</b>	<b>-0.0</b>	<b>0.1</b>	<b>-</b>
<b>PROFIT OR LOSS</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

Non-recurring expenses related to the free share grant reclassified as operating income are broken down into “wages,” “social security contributions” and “other operating expenses.”

- accounting entries of a purely tax nature, as defined and provided for in the regulations of the French accounting standards authority (Autorité des normes comptables - ANC). This applies to the creation or reversal of regulated provisions, including accelerated depreciation recognized for tax purposes and defined in Article 214-8;
- changes in accounting policy that the entity is required to recognize in profit or loss, rather than equity, as a result of the application of tax rules;
- corrections of errors, except when correcting an entry that has been directly recorded to equity.

The new provisions of the Regulation apply since 2025, with no impact on the 2024 financial statements other than the reclassifications necessary for the new presentation of the balance sheet and profit & loss statement. In 2024, the balance sheet and profit & loss statement were presented as follows:

## BALANCE SHEET - ASSETS

<i>In millions of euros</i>	<b>Net 12/31/2024</b>
<b>NON-CURRENT ASSETS</b>	
Intangible assets	167.9
Property, plant and equipment	373.5
Investments and related receivables	1,047.1
Other non-current financial assets	124.4
<b>Total</b>	<b>1,712.9</b>
<b>CURRENT ASSETS</b>	
Inventories and work-in-progress	234.3
Trade receivables	514.9
Other operating receivables	51.3
Non-operating receivables	49.5
Cash and cash pooling	878.3
<b>Total</b>	<b>1,728.3</b>
Deferred charges spread over several years	0.3
Translation differences – losses	9.1
<b>TOTAL ASSETS</b>	<b>3,450.6</b>

## BALANCE SHEET - LIABILITIES

<i>In millions of euros</i>	<b>12/31/2024</b>
<b>SHAREHOLDERS' EQUITY</b>	
Share capital	12.0
Additional paid-in capital	74.4
Reserves	1,197.3
Statutory provisions and grants	84.3
Net income for the year	451.9
<b>Total</b>	<b>1,819.9</b>
<b>Provisions</b>	<b>81.1</b>
<b>LIABILITIES</b>	
Borrowings and financial debt	928.6
Trade payables	334.7
Other operating payables	258.6
Non-operating payables	27.2
<b>Total</b>	<b>1,549.1</b>
Translation differences – gains	0.5
<b>TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES</b>	<b>3,450.6</b>

## PROFIT &amp; LOSS STATEMENT

<i>In millions of euros</i>	2024
Sales of goods and finished products	1,277.4
Other income	363.3
<b>Sales</b>	<b>1,640.7</b>
Production included in inventories (work-in-progress and finished products)	-18.4
Capitalized production	9.4
<b>Total production</b>	<b>1,631.7</b>
Purchases	-638.5
Change in raw material and instrument inventories	-9.1
External expenses	-449.5
<b>Added value</b>	<b>534.6</b>
Taxes other than income tax	-16.8
Payroll and benefits	-440.0
<b>Gross operating income (EBITDA)</b>	<b>77.8</b>
Depreciation, amortization and provisions	-77.7
Other operating income (expense)	-13.9
<b>Operating income</b>	<b>-13.8</b>
Financial income and expenses	-0.8
Net investment income	452.8
<b>Net income before non-recurring items and tax</b>	<b>438.3</b>
Non-recurring income	-3.1
Income tax	16.7
<b>NET INCOME</b>	<b>451.9</b>

## NOTE 2 Information about the entity that prepares the consolidated financial statements

The Company prepares consolidated financial statements which include the annual financial statements of its subsidiaries based on the full consolidation method whenever bioMérieux SA has effective control over those subsidiaries, or based on the equity

method when the Company exercises significant leverage over the entities concerned.

The Company has been included in the scope of consolidation on a fully consolidated basis by Compagnie Mérieux Alliance.

### Information about the entity that prepares the consolidated financial statements

Entity preparing the consolidated financial statements of the largest group of entities of which the entity is a subsidiary	<b>Compagnie Mérieux Alliance</b> 17, rue Bourgelat, 69002 - Lyon SIREN 504,340,407
Entity preparing the consolidated financial statements of the smallest group of entities included in the above group of entities of which the entity is a subsidiary	<b>Institut Mérieux</b> 17, rue Bourgelat, 69002 - Lyon SIREN 348,579,509

## NOTE 3 Significant events of the fiscal year

### 3.1 Financial investments

In 2025, bioMérieux SA subscribed to several equity investments and capital increases in its portfolio for a total amount of €194.4 million, including the acquisition of the entire share capital of

SpinChip Diagnostics for NOK 1.3 billion (€112.3 million) and the capital increase of some of its subsidiaries for €77.9 million.

These events are detailed in Note 4.4.

### 3.2 Employee share ownership plan

In 2025, eligible Group employees participated in a private placement within an employee share ownership plan called "MyShare." Employees benefited from a share subscription price of €91.84 discounted by 20% compared with the reference price (€114.8) and a matching employer contribution of 100% of the subscription amount up to a maximum of €450 per employee. Group employees subscribed to 177,262 shares (of which 113,556 shares by French employees). The Company issued 203,210 shares to employees (of which 129,492 shares for French

employees) taking into account the discount and the matching employer contribution. The cost of the plan for French employees, as recorded in operating income, is €4.8 million. The cost of the plan for employees of other Group companies has been fully passed on to the subsidiaries and has no impact on operating income. The difference between the reference share price (€114.8) and the cost price (€100.27) of the 203,210 shares granted to the Group's employees represents a gain €3 million in financial income.

### 3.3 Significant subsequent events

There have been no significant events since the balance sheet date.

## NOTE 4 Non-current assets

### 4.1 General framework

Gross value <i>In millions of euros</i>	Gross amount at the beginning of the fiscal year	Increases	Decreases	Gross amount at year-end
Intangible assets	346.9	131.7	-46.8	431.9
Property, plant and equipment	904.4	123.6	-39.3	988.7
Non-current financial assets	1,354.6	198.0	-4.1	1,548.5
<b>TOTAL</b>	<b>2,605.9</b>	<b>453.3</b>	<b>-90.1</b>	<b>2,969.1</b>

Amortization <i>In millions of euros</i>	Duration of use	Amortization method	Accumulated amortization at the beginning of the year	Increases: Allocations for the fiscal year	Decreases	Accumulated amortization at year-end
Intangible assets	1 to 20 years	straight-line	167.4	17.0	-34.4	150.0
Property, plant and equipment	3 to 40 years	straight-line	528.8	47.0	-15.2	560.7
Non-current financial assets	N/A	N/A	-	-	-	-
<b>TOTAL</b>			<b>696.3</b>	<b>64.0</b>	<b>-49.6</b>	<b>710.7</b>

Impairment <i>In millions of euros</i>	Impairment losses at the beginning of the fiscal year	Increases: allocation for the fiscal year	Decreases: reversals for the fiscal year	Impairment at year-end
Intangible assets	11.5	-	-11.5	0.0
Property, plant and equipment	2.1	0.9	-0.7	2.4
Non-current financial assets	183.1	59.8	-1.2	241.8
<b>TOTAL</b>	<b>196.8</b>	<b>60.7</b>	<b>-13.3</b>	<b>244.1</b>

## 4.2 Intangible assets

### 4.2.1 Accounting principles

Pursuant to ANC Regulation 2015-06, technical merger losses were allocated in January 2016 to specific intangible asset accounts relating to acquired goodwill, such as commercial goodwill, technology and customer relations.

Historical goodwill and assets originating from the allocation of technical merger losses are not stand-alone items able to generate cash flow on their own. They are intrinsically attached to production plants, to the R&D supporting the acquired product line, to technology and to the sales forces that help move products through all the Group's distribution channels.

Acquired goodwill is therefore grouped together with the other assets of the technological range to which they are linked in order to constitute a homogeneous and stand-alone range. In practice, tests are performed to group together assets that serve

the same client typology (industrial microbiology laboratories) or health issue (pathology/detection of pathogens: microbiology, molecular biology or immunoassays). An impairment test is carried out systematically based on asset groups close to the groups identified at Group level (CGU) when analysis shows them to be fungible (monitoring and pooled management of acquired goodwill by technological product line and customer type).

At each fiscal year-end, the net value of the asset groups thus identified is compared with the current value of assets as determined from the discounted net cash flows generated by these assets (including acquired goodwill). An impairment is recorded if a loss of value is observed.

Lastly, no borrowing costs are included in the acquisition cost of intangible assets.

### 4.2.2 Change

#### 4.2.2.1 Gross value

<b>Gross value</b> <i>In millions of euros</i>	<b>Gross amount at the beginning of the fiscal year</b>	<b>Increases</b>	<b>Decreases</b>	<b>Gross amount at year-end</b>
Development expenses	14.2	-	-	14.2
Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets	182.8	129.9	-34.4	278.2
Goodwill	142.0	-	-10.0	131.9
Other intangible assets	5.4	-	-	5.4
Intangible assets under construction, advances and deposits	2.6	1.9	-2.3	2.1
<b>TOTAL INTANGIBLE ASSETS</b>	<b>346.9</b>	<b>131.7</b>	<b>-46.8</b>	<b>431.9</b>

The increases for the period are broken down as follows:

<b>Increases for the year</b> <i>In millions of euros</i>	<b>Breakdown of increases</b>		
	<b>Transfers between items</b>	<b>Additions</b>	
		<b>Acquisitions</b>	<b>Creations</b>
Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets	2.1	127.8	-
Intangible assets under construction, advances and deposits	-	1.2	0.7
<b>TOTAL INTANGIBLE ASSETS</b>	<b>2.1</b>	<b>129.0</b>	<b>0.7</b>

In 2025, bioMérieux SA acquired the intellectual property rights to the technologies of SpinChip Diagnostic ASA for €105.3 million and Day Zero Diagnostics for €18.1 million.

SpinChip Diagnostics ASA technology consists of the development of a high-performance point-of-care immunoassay system, specifically designed for the detection of myocardial infarction.

Day Zero Diagnostics has developed innovative technologies that integrate sample preparation directly from whole blood, sequencing, and advanced identification and antibiotic susceptibility testing (ID/AST).

The decreases for the period are broken down as follows:

Decreases for the fiscal year <i>In millions of euros</i>	Breakdown of decreases		
	Transfers between items	Disposals	
		Disposals	Discontinuation
Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets	-	-0.3	-34.1
Goodwill	-	-	-10.0
Intangible assets under construction, advances and deposits	-2.3	-	-
<b>TOTAL INTANGIBLE ASSETS</b>	<b>-2.3</b>	<b>-0.3</b>	<b>-44.1</b>

The decommissioning of patents and IT solutions concerns obsolete or terminated licenses, software, and IT projects.

The discontinuation of the NUCLESIS® range commercialization resulted in the write-off of goodwill for a gross amount of €10 million, fully depreciated

#### 4.2.2.2 Amortization

Amortization <i>In millions of euros</i>	Duration of use	Amortization method	Accumulated amortization at the beginning of the year	Increases: allocations	Decreases	Total accumulated amortization at year-end
Development expenses	2 to 5 years	Straight-line	14.2	-	-	14.2
Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets	1 to 20 years	Straight-line	148.9	16.6	-34.4	131.1
Other intangible assets	1 to 15 years	Straight-line	4.3	0.3	-	4.7
<b>TOTAL INTANGIBLE ASSETS</b>			<b>167.4</b>	<b>17.0</b>	<b>-34.4</b>	<b>150.0</b>

Amortization expenses for the period are broken down as follows:

Allocations for the fiscal year <i>In millions of euros</i>	Breakdown of allocations		
	On items amortized on a straight-line basis	On items amortized using another method	Non-recurring allocations
Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets	16.6	-	-
Other intangible assets	0.3	-	-
<b>TOTAL INTANGIBLE ASSETS</b>	<b>17.0</b>	<b>-</b>	<b>-</b>

Amortization reversals are explained as follows:

Decreases for the fiscal year <i>In millions of euros</i>	Breakdown of decreases	
	Items sold	Discontinued items
Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets	-0.3	-34.1
<b>TOTAL INTANGIBLE ASSETS</b>	<b>-0.3</b>	<b>-34.1</b>

### 4.2.2.3 Impairment losses

Impairment <i>In millions of euros</i>	Impairment at the beginning of the year	Increases: allocation	Decreases: reversals	Impairment at year-end
Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets	1.5	-	-1.5	0.0
Goodwill	10.0	-	-10.0	-
<b>TOTAL INTANGIBLE ASSETS</b>	<b>11.5</b>	<b>-</b>	<b>-11.5</b>	<b>0.0</b>

### 4.2.2.4 Technical losses

Technical merger losses are allocated as follows:

<i>In millions of euros</i>	Gross value	Amortization	Net value
<b>AES CHEMUNEX</b>			
Goodwill	111.0	-	111.0
Technology	6.4	4.7	1.6
Customer relationships	5.4	4.7	0.7
<b>Total AES Chemunex</b>	<b>122.8</b>	<b>9.4</b>	<b>113.4</b>
<b>ARGENE</b>			
Goodwill	19.4	-	19.4
Technology	11.5	11.1	0.4
<b>Total Argene</b>	<b>30.9</b>	<b>11.1</b>	<b>19.8</b>
<b>CEERAM</b>			
Technology	2.4	2.4	-
<b>Total Ceeram</b>	<b>2.4</b>	<b>2.4</b>	<b>-</b>
<b>TOTAL</b>	<b>156.1</b>	<b>23.0</b>	<b>133.2</b>

Goodwill impairment tests were performed on AES Chemunex and Argene. No indication of loss of value has been identified.

## 4.3 Property, plant and equipment

### 4.3.1 Accounting principles

Property, plant and equipment are shown on the balance sheet at purchase or production cost.

In accordance with the asset recognition rules in effect since January 1, 2005, components whose cost is significant in relation to the total cost of the main asset are recognized and depreciated separately if their useful life is not the same as that of the main asset.

The only property, plant and equipment to which this method applies are buildings.

Impairment tests are carried out for property, plant and equipment whenever events or market developments indicate that an asset may have declined in value. If the net book value exceeds the recoverable amount, an impairment loss is recognized to reduce the assets to their realizable value.

Most capitalized instruments are installed at customers' sites.

Lastly, no borrowing costs are included in the acquisition cost of property, plant and equipment.

## 4.3.2 Change

### 4.3.2.1 Gross value

<b>Gross value</b> <i>In millions of euros</i>	<b>Gross amount at the beginning of the fiscal year</b>	<b>Increases</b>	<b>Decreases</b>	<b>Gross amount at year-end</b>
Land	22.1	1.4	-	23.5
Buildings	356.9	11.6	-3.2	365.4
Technical installations, industrial equipment and tools	387.7	27.0	-10.9	403.8
Other property, plant and equipment	71.1	2.8	-3.1	70.8
Property, plant and equipment under construction, advances, and deposits.	66.6	80.7	-22.2	125.1
<b>TOTAL PROPERTY, PLANT AND EQUIPMENT</b>	<b>904.4</b>	<b>123.6</b>	<b>-39.3</b>	<b>988.7</b>

The increases for the period are broken down as follows:

<b>Increases for the year</b> <i>In millions of euros</i>	<b>Breakdown of increases</b>		
	<b>Transfers between items</b>	<b>Additions</b>	
		<b>Acquisitions</b>	<b>Creations</b>
Land	0.2	1.3	-
Buildings	7.8	3.8	-
Technical installations, industrial equipment and tools	13.6	4.2	9.2
Other property, plant and equipment	0.9	1.9	-
Property, plant and equipment under construction, advances, and deposits.	-	80.5	0.2
<b>TOTAL PROPERTY, PLANT AND EQUIPMENT</b>	<b>22.5</b>	<b>91.7</b>	<b>9.4</b>

Increases during the period mainly include investments made in the production of BioFire and SpotFire reagents at the La Balme site for €32.6 million, the construction of a new building in Marcy

dedicated to molecular biology for €11.8 million, and the construction of a research and development building in Grenoble for €9.3 million.

The decreases for the period are broken down as follows:

<b>Decreases for the fiscal year</b> <i>In millions of euros</i>	<b>Breakdown of decreases</b>		
	<b>Transfers between items</b>	<b>Disposals</b>	
		<b>Disposals</b>	<b>Discontinuation</b>
Buildings	-	-	-3.2
Technical installations, industrial equipment and tools	-	-3.8	-7.1
Other property, plant and equipment	-	-0.2	-2.9
Property, plant and equipment under construction, advances, and deposits.	-22.2	-	-
<b>TOTAL PROPERTY, PLANT AND EQUIPMENT</b>	<b>-22.2</b>	<b>-4.0</b>	<b>-13.1</b>

In 2025, an amount of €22.2 million in property, plant and equipment under construction at the beginning of the fiscal year was brought into service, consisting mainly of production lines and industrial equipment.

## 4.3.2.2 Amortization

<b>Amortization</b> <i>In millions of euros</i>	<b>Duration of use</b>	<b>Amortization method</b>	<b>Accumulated amortization at the beginning of the year</b>	<b>Increases: allocations</b>	<b>Decreases</b>	<b>Accumulated amortization at the balance sheet date</b>
Land	N/A	N/A	1.5	0.1	-	1.6
Buildings	10 to 40 years	Straight-line	218.6	15.6	-3.2	231.0
Technical installations, industrial equipment and tools	3 to 10 years	Straight-line	252.2	27.0	-9.2	270.1
Other property, plant and equipment	3 to 10 years	Straight-line	56.5	4.3	-2.9	58.0
Property, plant and equipment under construction, advances, and deposits.	N/A	N/A	-	-	-	-
<b>TOTAL PROPERTY, PLANT AND EQUIPMENT</b>			<b>528.8</b>	<b>47.0</b>	<b>-15.2</b>	<b>560.7</b>

Amortization expenses for the period are broken down as follows:

<b>Allocations for the fiscal year</b> <i>In millions of euros</i>	<b>Breakdown of allocations</b>		
	<b>On items amortized on a straight-line basis</b>	<b>On items amortized using another method</b>	<b>Non-recurring allocations</b>
Land	0.1	-	-
Buildings	15.6	-	-
Technical installations, industrial equipment and tools	27.0	-	-
Other property, plant and equipment	4.3	-	-
<b>TOTAL PROPERTY, PLANT AND EQUIPMENT</b>	<b>47.0</b>	<b>-</b>	<b>-</b>

Amortization reversals are explained as follows:

<b>Decreases for the fiscal year</b> <i>In millions of euros</i>	<b>Breakdown of decreases</b>	
	<b>Items sold</b>	<b>Items taken out of service</b>
Buildings	-	-3.2
Technical installations, industrial equipment and tools	-2.0	-7.1
Other property, plant and equipment	-	-2.9
<b>TOTAL PROPERTY, PLANT AND EQUIPMENT</b>	<b>-2.0</b>	<b>-13.1</b>

## 4.3.2.3 Impairment losses

<b>Impairment</b> <i>In millions of euros</i>	<b>Impairment at the beginning of the year</b>	<b>Increases: allocation</b>	<b>Decreases: reversals</b>	<b>Impairment at year-end</b>
Buildings	0.7	-	-0.3	0.4
Technical installations, industrial equipment and tools	1.4	0.9	-0.4	2.0
<b>TOTAL PROPERTY, PLANT AND EQUIPMENT</b>	<b>2.1</b>	<b>0.9</b>	<b>-0.7</b>	<b>2.4</b>

## 4.4 Non-current financial assets

### 4.4.1 Accounting principles

Non-current financial assets are recognized at their purchase price.

An impairment loss is recognized on equity investments whenever their value in use falls below their acquisition cost. Value in use is initially estimated at the net book value of the subsidiary's assets at the closing date. This may be adjusted to reflect the value of any unrecognized identifiable assets (particularly real estate or technologies). Depending on the economic and financial condition of the subsidiary, value in use may also be estimated taking account of sales, borrowings and any associated technological assets and real estate. Given the specific nature of certain investments, in some cases value in use may be measured by estimating the enterprise value based on discounted future cash flows or on observable market financial inputs.

Non-controlling interests held in unlisted companies are measured based on various criteria including the economic outlook, the net equity of the investment or the valuation used based on recent investments in these shares.

Other investments are subjected to impairment whenever their market value falls below cost. The market value of listed securities corresponds to the average trading price during the last month of the fiscal year.

Other non-current financial assets include treasury shares purchased under a liquidity agreement with an investment firm for the specific purpose of maintaining an orderly market in the Company's shares. Treasury stock is measured at its average trading price during the last month of the fiscal year.

### 4.4.2 Change

#### 4.4.2.1 Gross value

Gross value <i>In millions of euros</i>	Gross amount at the beginning of the fiscal year	Increases	Decreases	Gross amount at year-end
Equity investments	1,161.8	192.6	-	1,354.5
Receivables from equity investments	6.2	2.9	-3.9	5.2
Other financial assets	186.0	2.4	-0.1	188.3
Other non-current financial assets	0.6	0.1	-0.1	0.6
<b>TOTAL NON-CURRENT FINANCIAL ASSETS</b>	<b>1,354.6</b>	<b>198.0</b>	<b>-4.1</b>	<b>1,548.5</b>

#### Acquisition of SpinChip Diagnostics ASA

In 2025, bioMérieux SA acquired the entire Norwegian company SpinChip Diagnostics ASA for NOK 1.3 billion, or €112.3 million. During the previous year, bioMérieux SA acquired a stake in this company for NOK 115 million (€9.9 million), and subscribed to a capital increase of NOK 12 million (€1 million).

- bioMérieux Brazil for 36.9 million Brazilian reals, i.e. €5.9 million;
- bioMérieux Nigeria for an amount of €3.4 million, through the conversion of debts into capital;
- bioMérieux Chile for €2.5 million;
- bioMérieux Regional Headquarters in Saudi Arabia, for an amount of SAR 3 million (€0.7 million).

Additionally, bioMérieux SA also participated in the capital increase of Aurobac Therapeutics SAS for an amount of €2.5 million.

#### Financial support to subsidiaries and minority interests

In 2025, bioMérieux SA subscribed to several capital increases of its subsidiaries, totaling €77.9 million, to support their commercial activities, acquisitions, and address cash difficulties stemming from currency devaluations:

- bioMérieux China for \$44.7 million, i.e. €38.3 million;
- bioMérieux Egypt for €13 million;
- bioMérieux Argentina for €8 million;
- bioMérieux Colombia for \$7 million, i.e. €6 million;

#### Transactions relating to fixed assets

bioMérieux SA acquired a €1.3 million stake in Plair, thereby strengthening its commitment to real-time microbial detection and air sampling solutions for the pharmaceutical industry.

Lastly, bioMérieux SA invested €0.4 million in Allergen Alert, a company working on the design of a system for non-professionals to quickly and reliably test for allergens in food.

## 4.4.2.2 Impairment losses

Impairment losses <i>In millions of euros</i>	Impairment at the beginning of the year	Increases: allocation	Decreases: reversals	Impairment at year-end
Equity investments	119.9	43.3	-0.0	163.1
Receivables from equity investments	1.1	-	-1.1	-
Other financial assets	62.2	16.5	-0.1	78.7
<b>TOTAL NON-CURRENT FINANCIAL ASSETS</b>	<b>183.1</b>	<b>59.8</b>	<b>-1.2</b>	<b>241.8</b>

Allocations to impairment of equity investments amounted to €43.3 million over the fiscal year, and relate to impairment of the shares in the subsidiaries bioMérieux China for €33 million, bioMérieux Egypt for €7.6 million, and bioMérieux Nigeria for €2.6 million.

Allocations to impairment of other fixed assets relate to impairment of the shares of Oxford Nanopore Technologies for €16.5 million (impairment losses calculated on the basis of the December 2025 stock exchange price compared to the acquisition price).

## 4.4.3 List of subsidiaries and minority interests

See table below.

## LIST OF SUBSIDIARIES AND MINORITY INTERESTS AT DECEMBER 31, 2025

Subsidiaries and minority interests	Financial information									
	Shareholders' equity*	Share of capital held (in %)	Book value of securities held (in millions of euros)		Net amount of loans and advances made by the Company (In millions of euros)	Amount of commitments given by the Company (In millions of euros)	Pre-tax sales for the last fiscal year (In millions of euros)	Net profit or net loss of the last fiscal year (In millions of euros)	Dividends received by Company during the fiscal year (In millions of euros)	Notes
			Gross	Net						
<b>INFORMATION CONCERNING SUBSIDIARIES (OVER 50% OWNED BY BIOMÉRIEUX SA)</b>										
<b>1. Detailed information for each subsidiary (1)</b>			<b>1,211.4</b>	<b>1,062.0</b>	<b>125.1</b>	<b>93.0</b>			<b>342.8</b>	
AB bioMérieux	47.8	100.0%	74.2	4.3	0.0	0.0	0.0	0.0	0.0	01/01/2025-12/31/2025
bioMérieux West Africa	890.5	100.0%	0.3	0.3	0.0	0.0	0.0	1.4	0.0	01/01/2025-12/31/2025
bioMérieux Germany	29.1	100.0%	3.8	3.8	0.0	0.0	141.1	2.6	1.0	01/01/2025-12/31/2025
bioMérieux Algeria	293.9	100.0%	0.6	0.6	0.0	0.0	0.6	0.4	0.0	01/01/2025-12/31/2025
bioMérieux Saudi Arabia	4.1	100.0%	0.7	0.7	0.0	0.0	0.0	0.2	0.0	01/01/2025-12/31/2025
bioMérieux Argentina	24,236.3	99.1%	16.3	16.3	0.0	0.3	27.9	5.3	0.0	01/01/2025-12/31/2025
bioMérieux Austria	1.2	100.0%	0.1	0.1	0.0	0.0	30.5	1.0	1.6	01/01/2025-12/31/2025
bioMérieux Australia	11.7	100.0%	23.8	23.8	0.0	0.7	36.1	0.8	0.5	01/01/2025-12/31/2025

Financial information

Subsidiaries and minority interests	Shareholders' equity*	Share of capital held (in %)	Book value of securities held (in millions of euros)		Net amount of loans and advances made by the Company (In millions of euros)	Amount of commitments given by the Company (In millions of euros)	Pre-tax sales for the last fiscal year (In millions of euros)	Net profit or net loss of the last fiscal year (In millions of euros)	Dividends received by Company during the fiscal year (In millions of euros)	Notes
			Gross	Net						
bioMérieux Brazil	147.0	100.0%	67.1	33.6	0.0	10.9	42.6	0.3	0.0	01/01/2025-12/31/2025
bioMérieux Belgium	3.0	100.0%	0.3	0.3	0.0	0.0	36.5	1.5	3.9	01/01/2025-12/31/2025
bioMérieux Canada	11.9	100.0%	20.5	20.5	0.0	0.0	64.4	1.6	0.9	01/01/2025-12/31/2025
bioMérieux Chile	15,631.5	100.0%	5.6	5.6	0.0	0.0	33.7	1.1	0.0	01/01/2025-12/31/2025
bioMérieux China	2,202.8	100.0%	228.6	195.6	0.0	0.6	27.7	0.7	0.0	01/01/2025-12/31/2025
bioMérieux Colombia	108.7	100.0%	14.0	14.0	0.0	0.0	45.4	2.7	0.0	01/01/2025-12/31/2025
bioMérieux Korea	27,994.8	100.0%	0.7	0.7	0.0	10.0	53.3	1.8	0.0	01/01/2025-12/31/2025
bioMérieux Denmark	6.7	100.0%	0.5	0.5	0.0	0.0	9.6	0.3	0.5	01/01/2025-12/31/2025
bioMérieux Spain	36.8	100.0%	0.6	0.6	0.0	0.0	130.0	4.6	6.0	01/01/2025-12/31/2025
bioMérieux Egypt	303.5	100.0%	14.5	5.4	0.0	0.0	2.1	-7.0	0.0	01/01/2025-12/31/2025
bioMérieux Greece	7.3	100.0%	4.1	4.1	0.0	3.0	22.6	0.0	0.0	01/01/2025-12/31/2025
bioMérieux India	4,322.3	99.9%	18.1	18.1	0.0	21.3	107.6	4.1	0.0	01/01/2025-12/31/2025
bioMérieux Inc.	2,250.0	100.0%	524.9	524.9	55.8	12.3	2,556.9	658.3	303.8	01/01/2025-12/31/2025
bioMérieux Italy	54.6	100.0%	12.8	12.8	11.9	25.8	186.8	10.6	4.0	01/01/2025-12/31/2025
bioMérieux Japan	2.6	100.0%	15.4	15.4	15.4	0.5	116.4	5.0	1.4	01/01/2025-12/31/2025
bioMérieux Kenya	112.4	100.0%	0.3	0.3	0.0	0.0	0.0	0.0	0.0	01/01/2025-12/31/2025
bioMérieux Mexico	414.5	100.0%	24.7	24.7	27.1	0.0	69.5	0.6	0.0	01/01/2025-12/31/2025
bioMérieux Nigeria	1,343.1	100.0%	4.7	0.8	0.0	0.0	0.7	-0.1	0.0	01/01/2025-12/31/2025
bioMérieux Norway	5.0	100.0%	0.3	0.3	0.3	0.0	7.1	0.2	0.3	01/01/2025-12/31/2025
bioMérieux Philippines	72.9	100.0%	0.2	0.2	0.0	1.5	22.7	0.4	0.0	01/01/2025-12/31/2025
bioMérieux Poland	47.6	100.0%	1.5	1.5	0.9	0.0	43.6	1.4	0.0	01/01/2025-12/31/2025
bioMérieux Portugal	7.7	100.0%	2.0	2.0	0.0	0.5	24.4	1.3	1.0	01/01/2025-12/31/2025

Subsidiaries and minority interests	Shareholders' equity*	Share of capital held (in %)	Book value of securities held (in millions of euros)		Net amount of loans and advances made by the Company (In millions of euros)	Amount of commitments given by the Company (In millions of euros)	Pre-tax sales for the last fiscal year (In millions of euros)	Net profit or net loss of the last fiscal year (In millions of euros)	Dividends received by Company during the fiscal year (In millions of euros)	Notes
			Gross	Net						
			Financial information							
bioMérieux Russia	1,307.3	100.0%	1.3	1.3	0.0	0.0	17.8	2.1	0.0	01/01/2025-12/31/2025
bioMérieux South Africa	184.9	100.0%	5.4	5.4	5.2	0.0	26.9	0.5	0.0	01/01/2025-12/31/2025
bioMérieux Sweden	11.2	100.0%	0.2	0.2	1.8	2.8	30.8	0.5	0.5	01/01/2025-12/31/2025
bioMérieux Switzerland	4.1	100.0%	0.6	0.6	0.0	0.0	50.2	1.9	2.2	01/01/2025-12/31/2025
bioMérieux Suzhou Biotech Co.	388.7	100.0%	80.2	80.2	0.0	0.0	23.2	-0.6	0.0	01/01/2025-12/31/2025
bioMérieux Thailand	117.9	100.0%	0.9	0.9	0.0	0.8	17.8	0.4	0.5	01/01/2025-12/31/2025
bioMérieux Turkey	961.2	100.0%	17.0	17.0	0.0	0.0	38.9	5.4	0.6	01/01/2025-12/31/2025
bioMérieux UK	15.6	100.0%	1.2	1.2	4.0	0.7	109.9	2.8	0.0	01/01/2025-12/31/2025
bioMérieux Vietnam	12.5	100.0%	0.2	0.2	0.0	0.0	0.0	0.0	0.0	01/01/2025-12/31/2025
BTF	60.4	100.0%	13.6	13.6	0.0	1.2	35.1	18.6	14.1	01/01/2025-12/31/2025
Lumed Inc.	11.1	100.0%	9.7	9.7	2.8	0.0	0.3	-1.5	0.0	01/01/2025-12/31/2025
<b>2. Overall information for equity investments not included in (1)</b>			<b>126.8</b>	<b>124.3</b>	<b>78.9</b>	<b>2.4</b>			<b>7.1</b>	
<b>A. TOTAL SUBSIDIARIES</b>			<b>1,338.2</b>	<b>1,186.4</b>	<b>204.0</b>	<b>95.4</b>			<b>349.9</b>	
<b>INFORMATION CONCERNING EQUITY INVESTMENTS (10% TO 50% OF CAPITAL HELD BY BIOMÉRIEUX SA)</b>										
<b>1. Detailed information for each subsidiary (1)</b>			<b>5.0</b>	<b>5.0</b>	<b>0.0</b>	<b>0.0</b>			<b>0.0</b>	
Aurobac Therapeutics SAS	13.1	12.5%	5.0	5.0	0.0	0.0	0.0	-4.7	0.0	01/01/2024-12/31/2024
<b>2. Overall information for equity investments not included in (1)</b>			<b>4.2</b>	<b>0.0</b>	<b>1.6</b>	<b>0.0</b>			<b>0.0</b>	
<b>B. TOTAL MINORITY INTERESTS</b>			<b>9.2</b>	<b>5.0</b>	<b>1.6</b>	<b>0.0</b>			<b>0.0</b>	
<b>C. TOTAL SUBSIDIARIES AND MINORITY INTERESTS (A + B)</b>			<b>1,347.4</b>	<b>1,191.4</b>	<b>205.7</b>	<b>95.4</b>			<b>349.9</b>	

\* In transaction currencies.

## NOTE 5 Inventories

### 5.1 Accounting principles

Inventories are measured at the lower of cost and net realizable value.

Inventories of raw materials, consumables and goods for resale are measured at their purchase price plus related expenses using the FIFO method. Work-in-progress and finished products are measured at their actual production cost.

Inventories are written down where necessary, taking into account selling prices, obsolescence, residual shelf life, product condition, sale prospects and, in the case of spare parts, changes in the corresponding instruments' installed base.

### 5.2 Change

#### Inventories and work-in-progress

In millions of euros

	12/31/2025	12/31/2024
Raw materials other supplies	45.3	48.2
Work-in-progress	30.2	33.9
Finished products	41.6	40.1
Goods held for sale	136.8	122.9
<b>TOTAL</b>	<b>253.9</b>	<b>245.2</b>

#### Impairment of inventories and work-in-progress

In millions of euros

	12/31/2025	12/31/2024	Method used to calculate impairment
Raw materials other supplies	-2.8	-2.5	Expiration, use, scrapping
Work-in-progress	-0.8	-1.4	Identified risks of non-use
Finished products	-1.4	-1.6	Sales prospects and scrapping
Goods held for sale	-5.6	-5.3	Sales prospects and scrapping
<b>TOTAL</b>	<b>-10.6</b>	<b>-10.9</b>	

The net value of inventories increased by €8.9 million compared with December 31, 2024, mainly due to an €11.7 million increase in inventories of BioFire reagents.

## NOTE 6 Trade and other receivables from current assets

### 6.1 Accounting principles

Receivables are recognized at face value. An impairment loss is recognized when there is a risk of non-recovery.

### 6.2 Change

#### Trade receivables

In millions of euros

	12/31/2025	12/31/2024
Gross trade receivables	574.1	537.1
Impairment losses	-13.8 <sup>(a)</sup>	-22.2
<b>NET VALUE</b>	<b>560.3</b>	<b>514.9</b>

(a) The decrease compared with 2024 is due to the absence of impairment of intra-group trade receivables at December 31, 2025, compared with €8.4 million at December 31, 2024.

<b>Other operating receivables</b> <i>In millions of euros</i>	<b>12/31/2025</b>	<b>12/31/2024</b>
Advances and deposits	14.8 <sup>(a)</sup>	8.9
Prepaid expenses	21.7 <sup>(b)</sup>	16.4
Other receivables	91.1 <sup>(c)</sup>	75.5
<b>TOTAL</b>	<b>127.5</b>	<b>100.8</b>

(a) Of which €10.4 million in advances paid, unused portion at December 31, 2025, which will be charged to future royalties over the next five years.

(b) Prepaid expenses primarily consist of external expenses.

(c) Including VAT receivables of €23.3 million at December 31, 2025, (against €19.1 million at December 31, 2024). Other receivables also include research tax credit receivables.

## NOTE 7 Due dates of receivables

<b>Statement of receivable due dates</b> <i>In millions of euros</i>	<b>Gross amounts</b>	<b>Due within 1 year</b>	<b>Due in more than 1 year</b>
Receivables from non-current assets	45.6	40.0	5.6
Receivables from current assets	680.0	625.6	54.3 <sup>(a)</sup>
Prepaid expenses	21.7	20.2	1.5
<b>TOTAL</b>	<b>747.3</b>	<b>685.8</b>	<b>61.4</b>

(a) Receivables from current assets due in more than one year mainly correspond to research tax credit receivables.

## NOTE 8 Cash and cash equivalents and investment securities

### 8.1 Accounting principles

Cash and cash equivalents include available cash and short-term investments.

Changes in the cash pool are valued at the average monthly exchange rate. Cash pooling accounts are remeasured at the end of the month at the closing rate. This remeasurement is offset by an entry to financial income and expense reflecting currency hedges related to these positions.

### 8.2 Change

<b>Cash and cash equivalents and investments</b> <i>In millions of euros</i>	<b>12/31/2025</b>	<b>12/31/2024</b>
Cash investments	213.6	172.9
Lender cash pooling	224.0	529.8
Cash	183.0	172.9
Financial instruments	1.8	2.8
<b>TOTAL CASH AND CASH EQUIVALENTS</b>	<b>622.4</b>	<b>878.3</b>

Cash investments break down as follows:

<b>Investments</b> <i>In millions of euros</i>			<b>12/31/2025</b>	<b>12/31/2024</b>
<b>Investment</b>	<b>Classification</b>	<b>ISIN Code</b>		
Treasury shares	Equities	FR0013280286	35.5	39.1
BNP PARIBAS ISR IC money market fund	Euro money-market fund	FR0007009808	36.0	-
BNP PARIBAS SIGNATURE R money market fund	Euro money-market fund	FR0013245651	20.1	48.5
AMUNDI EURO LIQUIDITY money market fund	Euro money-market fund	FR0010251660	56.1	49.8
Time-deposit accounts	Euro money-market fund	N/A	65.8	35.4
<b>TOTAL</b>			<b>213.6</b>	<b>172.9</b>

Short-term investments include 331,541 shares purchased in connection with the establishment of a hedging program to cover the cost of the various free share grant plans and the employee share ownership programs.

Net debt is discussed in Note 12.1.

## NOTE 9 Translation differences

### 9.1 Accounting principles

In application of regulation ANC 2015-05, income and expenses in foreign currencies are recognized at their value in euros on the transaction date based on the average monthly exchange rate. Foreign exchange gains or losses on commercial transactions that result from differences in rates between the transaction date and the settlement date are recognized on the corresponding line in the profit & loss statement (sales and purchases).

Receivables and payables in foreign currencies are converted based on their exchange rate on the closing date of the fiscal year. Differences resulting from this valuation were recognized under unrealized translation differences. Provisions are created for unrealized translation differences (losses) and are recognized in income (sales and purchases) whenever the receivable or payable is related to a business transaction.

When, for business transactions with relatively close maturities, unrealized foreign exchange gains and losses may be considered as contributing to an overall currency position, the amount added to the provision for exchange rate risks is capped at the excess of losses over gains. This estimate of losses factors in, when applicable, the hedge rate on the derivatives covering such transactions.

Foreign exchange gains and losses concerning financial flows are recognized in financial income and expenses. Translation differences concerning cash pooling are recognized in income, as are hedging instruments, symmetrically with the hedged item.

### 9.2 Translation differences – losses

<i>In millions of euros</i>	12/31/2025	12/31/2024
On borrowings and operating receivables	0.8	6.0
On borrowings and financial receivables	1.3	3.1
<b>TOTAL</b>	<b>2.1</b>	<b>9.1</b>

### 9.3 Translation differences – gains

<i>In millions of euros</i>	12/31/2025	12/31/2024
On borrowings and operating receivables	1.2	0.5
<b>TOTAL</b>	<b>1.2</b>	<b>0.5</b>

## NOTE 10 Equity and free shares grant plans

### 10.1 Accounting principles

As of December 31, 2024, the Company applies ANC Regulation 2024-02 on the recognition of energy efficiency certificates. Energy savings certificates are now recognized in operating income at the disposal date, and those prior to 2024 have been reclassified as retained earnings for an amount of €1.5 million.

## 10.2 Change in equity

Change in shareholders' equity <i>In millions of euros</i>	Amount at the beginning of the fiscal year	Net income for the year	Dividends paid	Statutory provisions and grants	Amount at the end of the fiscal year
Share capital	12.0				12.0
Additional paid-in capital	74.4				74.4
Reserves & income	1,649.2	320.5	-106.1		1,863.6
Statutory provisions	84.1				84.1
Subsidies	0.1			0.0	0.2
<b>TOTAL</b>	<b>1,819.9</b>	<b>320.5</b>	<b>-106.1</b>	<b>0.0</b>	<b>2,034.3</b>

The Company's share capital amounted to €12,029,370 at December 31, 2025 and was divided into 118,361,220 shares with a total of 152,167,288 voting rights (of which 75,630,589 shares carry double voting rights). Following a decision taken by the Annual General Meeting of March 19, 2001, the Company's articles of association no longer refer to a par value for its shares. No rights or securities with a dilutive impact on capital were outstanding at December 31, 2025.

At December 31, 2025, the Company held:

- 41,528 treasury shares under a liquidity agreement with an outside firm. In 2025, the Company purchased 1,101,650 and sold 1,097,784 treasury shares;
- 331,541 treasury shares were purchased as part of a hedging program for the various free share grant plans and employee share ownership plans. At December 31, 2025, these shares were not specifically allocated to one plan. In 2025, the Company purchased 375,000 shares and awarded 445,519.

The following table presents the Company's free share grant plans:

Number of shares	Date on which plans opened				Total
	2022	2023	2024	2025	
Initial number of options granted	272,218	287,538	406,257	369,255	1,335,268
Options canceled	-29,909	-37,903	-61,366	-110,995	-240,173 <sup>(a)</sup>
Number of shares remitted over the period	-242,309	-	-	-	-242,309
<b>NUMBER OF SHARES TO BE REMITTED AT THE BALANCE SHEET DATE</b>	<b>-</b>	<b>249,635</b>	<b>344,891</b>	<b>258,260</b>	<b>852,786</b>

(a) Of which 77,719 shares canceled due to employee departures and 162,454 shares canceled due to assumptions that performance criteria would be met.

Between 2022 and 2025, the Board of Directors granted free shares to certain employees and corporate officers. These plans specify that the free shares will have a vesting period of three years. Vesting conditions are related to continuous employment conditions and performance criteria subject to the achievement of objectives based on revenue and contributive operating income before non-recurring items, growth in these indicators,

or the achievement of specific non-financial objectives. The performance shares are no longer subject to a lock-up period if the vesting period is at least two years. The lock-up period may be waived for shares granted to non-French tax residents provided that the shares concerned are subject to a three-year vesting period.

In 2025, after taking into account all free shares that were re-invoiced, a net expense of €19.3 million was recognized in operating income, compared to a net expense of €11.7 million the previous year.

At December 31, 2025, the company considered that the performance criteria would be met for 852,786 free shares.

However, 162,454 free shares are considered canceled due to the risk of the performance criteria will not be met.

With the 331,541 treasury shares held at December 31, 2025, the Company will have to purchase a maximum of 521,245 additional shares at a cost of €57 million, based on the share price at December 31, 2025, to cover existing plans.

### 10.3 Change in regulated provisions and investment grants

Regulated provisions and investment subsidies <i>In millions of euros</i>	Amount at the beginning of the fiscal year	Increases: allocations for the fiscal year	Decreases: reversals for the fiscal year	Amount at the end of the fiscal year
Accelerated depreciation and amortization	78.1	13.6	-13.5	78.2
Provisions for price increases	6.0	0.4	-0.5	6.0
Capital expenditure subsidies	0.1	0.0	-0.0	0.2
<b>TOTAL</b>	<b>84.3</b>	<b>14.0</b>	<b>-14.0</b>	<b>84.3</b>

## NOTE 11 Provisions for financial risks and losses

### 11.1 Change

Provisions for financial contingencies and losses <i>In millions of euros</i>	Amount at the beginning of the fiscal year	Increases: allocations for the fiscal year	Decreases: reversals for the fiscal year		Amount at the end of the fiscal year
			Used	N/A	
<b>Provisions for risks</b>	<b>12.6</b>	<b>2.9</b>	<b>-12.4</b>	<b>-0.2</b>	<b>2.9</b>
Guarantees given to customers	0.5	0.8	-0.5	-	0.8
Foreign exchange losses	9.1	2.1	-9.1	-	2.1
Financial risks	2.8	-	-2.8	-	-
Other risks	0.2	-	-	-0.2	-
<b>Provisions for charges</b>	<b>68.5</b>	<b>33.5</b>	<b>-26.6</b>	<b>-1.6</b>	<b>73.8</b>
Free share grant	40.1	29.6	-22.6	-	47.2
Long-service awards and end-of career benefits	23.3	-	-2.1	-	21.2
Other expenses	5.1	3.8	-1.9	-1.6	5.4
<b>TOTAL</b>	<b>81.1</b>	<b>36.3</b>	<b>-38.9</b>	<b>-1.9</b>	<b>76.6</b>

## 11.2 Provisions for pensions and other post-employment benefits

Post-employment benefit obligations and similar commitments are calculated using actuarial methods based on the following assumptions:

	Retirement benefits		Long-service awards	
	12/31/2025	12/31/2024	12/31/2025	12/31/2024
Salary increase rate	3.00%	3.00%	3.00%	3.00%
Discount rate	4.00%	3.30%	3.85%	3.10%
Employee mobility rate <sup>(a)</sup>	0 to 7%	0 to 7%	0 to 7%	0 to 7%
Average duration	12.7	13.2	8.7	8.9

(a) Depending on the age and status of the employee (managerial/non-managerial).

The actuarial valuation of employee benefit obligations is as follows:

In millions of euros	Retirement benefits		Long-service awards	
	12/31/2025	12/31/2024	12/31/2025	12/31/2024
Present value of obligation	40.2	41.0	16.1	16.2
Fair value of hedging assets	35.1	34.0		
<b>NET SITUATION</b>	<b>5.1</b>	<b>7.1</b>	<b>16.1</b>	<b>16.2</b>

The Company's obligations relating to retirement benefits are prefinanced by means of an insurance contract. The retirement benefits scheme represented a net debt of €5.1 million at December 31, 2025 vs. €7.1 million at December 31, 2024.

## NOTE 12 Net debt

### 12.1 Statement of changes in net debt

The statement of changes in net debt includes all changes in borrowings and financial debts, regardless of maturity, net of cash and short-term bank borrowings.

It lists separately:

- cash flows from operating activities;
- cash flows from investment activities;
- cash flows relating to shareholders' equity.

Cash flow from operating activities for the fiscal year corresponds to the aggregate of net income, depreciation and amortization, net additions to provisions (impairment and contingencies and losses), less capital gains or losses on disposals of fixed assets.

Net debt corresponds to the Company's financial situation with regard to financing third parties outside of operating payables. This aggregate is determined by the sum of bond and banking debt (short-, medium- and long-term) and current accounts in credit, less cash, investment securities and current accounts in debit.

<b>Table of changes in net debt</b> <i>In millions of euros</i>	<b>12/31/2025</b>	<b>12/31/2024</b>
Net income	320.5	451.9
Net change in amortization, impairment and provisions	92.5 <sup>(a)</sup>	90.1 <sup>(b)</sup>
Gains and losses on Corporate actions	10.0	0.4
<b>Cash flow from operating activities</b>	<b>423.0</b>	<b>542.3</b>
Change in inventories	-8.6 <sup>(c)</sup>	27.5
Change in trade receivables	-33.0 <sup>(d)</sup>	-28.1
Change in trade payables and other operating working capital	-1.9	116.8
<b>Change in operating working capital requirement</b>	<b>-43.5</b>	<b>116.1</b>
Change in receivables, net of tax	-16.5 <sup>(e)</sup>	-1.7
<b>Total change in working capital requirement</b>	<b>-60.0</b>	<b>114.5</b>
<b>Net cash from operating activities</b>	<b>362.9</b>	<b>656.8</b>
Capital expenditure	-230.7 <sup>(f)</sup>	-84.5
Income from sales of fixed assets	2.0	2.5
Change in net trade payables on fixed assets	4.9	-1.0
Acquisition of equity investments, subscr. to capital increases net of reductions	-192.7 <sup>(g)</sup>	-168.9 <sup>(h)</sup>
Net change in advances and loans to subsidiaries	3.2 <sup>(i)</sup>	12.2
Net change in other non-current financial assets	-3.4	0.4
<b>Net cash flows from (used in) investment activities</b>	<b>-416.7</b>	<b>-239.3</b>
Dividends paid	-106.1	-100.2
Capital expenditure subsidy		0.1
Merger		0.4
<b>Net cash used in shareholders' equity</b>	<b>-106.1</b>	<b>-99.8</b>
<b>Change in net debt (excluding exchange rate impact)</b>	<b>-159.9</b>	<b>317.7</b>
<b>Breakdown of change in net debt</b>		
Net debt at beginning of year	50.3	368.3
Impact of changes in exchange rates on net debt	0.7	-0.3
Impact of impairments of cash and cash equivalents	0.1	0.1
<b>Change in net debt</b>	<b>159.9</b>	<b>-317.7</b>
• Committed debt	6.0	-0.3
• Cash and bank overdrafts	153.9	-317.4
<b>NET DEBT AT END OF YEAR</b>	<b>210.9</b>	<b>50.3</b>

(a) Including amortization and impairment of property, plant, and equipment and intangible assets for €52.7 million, provisions for risks on securities of €55.9 million, deferred expenses of €0.1 million, net reversals of inventory impairment losses of €0.3 million, net reversals of provisions for risks and charges of €1.7 million, and impairment losses on receivables of €14.3 million.

(b) Including amortization and impairment of property, plant and equipment and intangible assets (€58 million), additions for risk on securities (€27.5 million), net additions to regulated provisions (€5.1 million), net additions to provisions for contingencies and losses (€5.1 million), net reversals of impairment of inventories (-€2.6 million) and impairment of receivables (-€2.9 million).

(c) Including an increase in inventories of €13.9 million.

(d) Including increases in Group trade receivables of €25.8 million, export trade receivables of €4.8 million, and domestic trade receivables of €2.3 million.

(e) Including a provision for the 2025 research tax credit of €15.9 million and tax disbursements of €4 million.

(f) Including property, plant and equipment for -€101.1 million (see Note 4.3) and intangible assets for -€129.7 million (see Note 4.2).

(g) Including acquisition of an equity investment in SpinChip Diagnostic ASA of -€112.3 million, capital increases in subsidiaries of -€77.9 million (detailed in Note 4.4) and subscription to the capital increase of Aurobac Therapeutics SAS of -€2.5 million.

(h) Including capital increases for subsidiaries of -€123.7 million, acquisition of an equity investment in bioMérieux Mexico of -€24.7 million, SpinChip Diagnostics ASA of -€10.9 million, Lumed Inc. of -€9.1 million, and release of capital in bioMérieux Nigeria of -€0.4 million.

(i) Including repayment of the intra-group loan to bioMérieux Egypt of €3.2 million.

## 12.2 Debt refinancing

At December 31, 2025, bioMérieux SA had a syndicated credit facility of €600 million. This syndicated credit facility matures in March 2028 (5 years). Following the exercise of two extension options in February 2024 and January 2025, its maturity was extended to 2030. On February 12, 2024, bioMérieux amended this syndicated credit facility agreement to include a margin adjustment mechanism based on the achievement of four Environmental, Social and Governance metrics. This syndicated credit facility has not been drawn on at December 31, 2025.

A €200 million Euro PP bond issue was launched in June 2020. It consists of two tranches, including a 10-year €55 million tranche at a rate of 1.902% and a seven-year €145 million tranche at a rate of 1.5%.

This syndicated credit facility and the Euro PP bond are subject to the following covenant: bioMérieux Group net debt may not exceed 3.5 times operating income before non-recurring items (EBITDA) before depreciation/amortization and acquisition-related costs. The Company complied with this covenant at December 31, 2025.

bioMérieux SA also has negotiable debt securities amounting to €16 million at December 31, 2025, compared with €10 million at December 31, 2024.

## 12.3 Change

### Breakdown of financial debts

In millions of euros

	12/31/2025	12/31/2024
Bond issues	201.6	201.6
Bank overdrafts and financial instruments	1.6	0.6
Borrower cash pooling	609.6	711.8
Other borrowings	20.5 <sup>(a)</sup>	14.6
<b>TOTAL BORROWINGS</b>	<b>833.4</b>	<b>928.6</b>

(a) Of which negotiable debt securities amounting to €16 million at December 31, 2025, compared with €10 million at December 31, 2024.

## 12.4 Debt schedule

### Net debt by maturity

In millions of euros

	12/31/2025	12/31/2024
Due beyond 5 years	-	55.0
Due in 1 to 5 years	204.5 <sup>(a)</sup>	149.6
<b>Total due beyond 1 year</b>	<b>204.5</b>	<b>204.6</b>
In less than one year	628.8 <sup>(b)</sup>	724.1
<b>Total borrowings</b>	<b>833.4</b>	<b>928.6</b>
Cash investments	-213.6 <sup>(c)</sup>	-172.9
Cash assets, financial instruments and lender cash pooling	-408.8 <sup>(d)</sup>	-705.5
<b>NET DEBT</b>	<b>210.9</b>	<b>50.3</b>

(a) Including a bond issue of €200 million (compared with €145 million at December 31, 2024).

(b) Including borrower cash pooling of €609.6 million, versus €711.8 million at December 31, 2024, which included a debt owed to BioFire Diagnostics of €436.8 million, (versus €656.8 million at December 31, 2024).

(c) Cash investments are described in Note 8.2.

(d) Including lender cash pooling for €224 million (compared with €529.8 million at December 31, 2024), including a receivable from Institut Mérieux of €62.9 million (nil at December 31, 2024) and from bioMérieux Inc. of €49.6 million (compared with €443.3 million at December 31, 2024).

## NOTE 13 Trade and other operating payables

### Trade and other payables

In millions of euros

	12/31/2025	12/31/2024
Trade payables	327.4	334.7
Tax and social-security debts	247.6	237.6
Debt to suppliers of non-current assets	31.1	27.2
Other payables	14.0	16.3
Deferred income	4.5 <sup>(a)</sup>	4.6
<b>TOTAL</b>	<b>624.6</b>	<b>620.5</b>

(a) Including rental and maintenance agreements for €3.9 million and the sale of reagents and instruments for €0.6 million.

## NOTE 14 Debt schedule

Statement of debt maturities at the end of the fiscal year <i>In millions of euros</i>	Gross amounts	Maturity within 1 year	Maturity within 1 and 5 years	Maturity over 5 years
Borrowings and similar debt	833.4	628.8	204.5	-
Trade payables	327.4	327.4	-	-
Other payables	292.7	198.1	23.5	71.1
Deferred income	4.5	4.2	0.3	-
<b>TOTAL</b>	<b>1,458.0</b>	<b>1,158.6</b>	<b>228.3</b>	<b>71.1</b>

## NOTE 15 Accrued expenses and income

Accrued expenses and income <i>In millions euros</i>	12/31/2025	12/31/2024
Miscellaneous borrowings and financial debt	1.7	1.7
Trade payables	55.3	54.3
Tax and social-security debts	228.8	219.9
Other operating payables	11.3	14.2
Other non-operating payables	14.2	11.5
<b>TOTAL ACCRUED EXPENSES</b>	<b>311.2</b>	<b>301.6</b>
<b>TOTAL ACCRUED INCOME</b>	<b>32.5 <sup>(a)</sup></b>	<b>53.7</b>

(a) Including unbilled revenue of €31.2 million at December 31, 2025, compared with €46.7 million at December 31, 2024.

## NOTE 16 Sales

### 16.1 Accounting principles

Revenue from product sales (reagents and instruments) and related services (after-sales, training, delivery, etc.) are presented in "Sales" on the profit & loss statement.

Sales arising from the sale of products is recognized when all of the following criteria have been satisfied:

- the significant risks and rewards of ownership have been transferred to the buyer;
- the Company no longer has a continuing involvement in the effective control over the goods sold;
- the revenue and the costs incurred or to be incurred in relation to the transaction can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the Company.

These criteria are satisfied when reagents are delivered and when sold instruments are installed.

In the case of services (training, after-sales service, etc.), sales are recognized only after the services have been rendered. Revenue from instrument maintenance contracts is deferred and recognized on the basis of the elapsed portion of the service contract.

Sales are measured at the fair value of the consideration received or receivable, net of any discounts and rebates granted to customers. Sales taxes and value-added taxes are not included in sales.

## 16.2 Change

<b>Breakdown of sales</b> <i>In millions of euros</i>	<b>France</b>	<b>Export</b>	<b>Total 12/31/2025</b>	<b>Total 12/31/2024</b>
<b>Sale of goods</b>	<b>109.2</b>	<b>614.5</b>	<b>723.7</b>	<b>672.8</b>
Sales of equipment and spare parts	8.1	159.6	167.7	154.0
Sales of reagents	101.1	454.0	555.1	518.3
Sales of services	-	0.9	0.9	0.5
<b>Production sold</b>	<b>122.7</b>	<b>847.9</b>	<b>970.5</b>	<b>967.9</b>
Sales of equipment and spare parts	1.3	9.0	10.3	9.4
Sales of reagents	90.8	459.9	550.7	583.4
Sales of services	30.6	379.0	409.5	375.1
<b>TOTAL</b>	<b>231.9</b>	<b>1,462.3</b>	<b>1,694.2</b>	<b>1,640.7</b>

<b>Sales by geographic area</b> <i>In millions of euros</i>	<b>12/31/2025</b>	<b>12/31/2024</b>
France & Overseas France	235.5	240.0
Europe, Africa, Middle East	798.8	761.6
South America	55.5	54.0
North America	128.9	125.0
Asia Pacific	114.9	132.8
Other related activities not broken down	360.6	327.3
<b>TOTAL</b>	<b>1,694.2</b>	<b>1,640.7</b>

## NOTE 17 Research & Development expenses

Research & Development expenses are recognized as expenses in the fiscal year in which they are incurred.

Research & Development expenses in fiscal year 2025 amounted to €195.8 million, compared to €166.3 million the previous year.

## NOTE 18 Personnel costs

### 18.1 Change

<b>Personnel costs</b> <i>In millions of euros</i>	<b>12/31/2025</b>	<b>12/31/2024</b>
Wages and salaries	246.3	242.4
Incentives, annual bonuses, and employee share ownership plans	76.0	63.9
Other personnel costs	8.1	8.0
Social security contributions	130.9	125.7
<b>TOTAL</b>	<b>461.4</b>	<b>440.1</b>

Pursuant to the statutory formula, the taxable net income for the 2025 fiscal year did not yield any amount in employee profit sharing.

Compensation allocated to members of administrative, management and supervisory bodies and senior management bodies (Company directors and members of the Executive Committee who are employees of the Company) in respect of their duties for the fiscal year consisted of fixed and variable compensation of €9.5 million and directors' fees of €0.4 million.

## 18.2 Headcount

### Breakdown of average headcount

In full-time equivalent

	2025
Production workers	491
Office workers, technicians, supervisors	1,070
Manager and engineers	2,555
<b>TOTAL</b>	<b>4,115</b>

## NOTE 19 Net financial income

### 19.1 Accounting principles

Dividends received are recognized net of withholding taxes applicable in the country of origin.

### 19.2 Change

Financial income In millions of euros	Income	Expenses	12/31/2025 Net	12/31/2024 Net
Impairment of investments	0.1	-59.8	-59.7 <sup>(a)</sup>	-28.1
Provisions for financial contingencies and losses	2.8	-	2.8	0.6
Impairment on cash pooling and loans	1.1	-0.1	1.0	0.0
Revenue from securities	349.9	-	349.9 <sup>(b)</sup>	480.3
Realized and unrealized foreign exchange gains and losses	119.8	-114.0	5.8	-0.4
Other financial income and expenses	26.8	-27.1	-0.2 <sup>(c)</sup>	-0.3
<b>TOTAL</b>	<b>500.4</b>	<b>-200.9</b>	<b>299.6</b>	<b>452.0</b>

(a) Including a net addition of €16.5 million for other fixed assets in 2025 (versus €27.3 million in 2024), and €10.2 million for equity investments in 2025 (versus €0.8 million in 2024).

(b) Including bioMérieux Inc. dividend payment of €303.8 million in 2025 (vs. €429.5 million in 2024). Dividends received from subsidiaries are described in the list of subsidiaries and minority interests in Note 4.4.3.

(c) Including a net financial expense of €8.1 million in interest on cash pooling (vs. €6.8 million in 2024).

### 19.3 Foreign exchange gains and losses

Foreign exchange gains and losses result from differences between the transaction exchange rate and the settlement rate (or the year-end rate if the payment has not yet been made). These differences only partially reflect the impact of currency fluctuations.

Foreign exchange gains and losses on commercial transactions are recognized under the relevant headings in the profit & loss statement. Foreign exchange gains and losses affect the profit & loss statement as follows:

In millions of euros	12/31/2025	12/31/2024
Operation	2.4	-6.8
Financial items	5.8	-0.4
<b>TOTAL</b>	<b>8.2</b>	<b>-7.2</b>

## NOTE 20 Non-recurring income

<b>Non-recurring income</b> <i>In millions of euros</i>	<b>Income</b>	<b>Expenses</b>	<b>Net 12/31/2025</b>	<b>Net 12/31/2024</b>
Exits and disposals of fixed assets	-	-	-	-0.1
Statutory provisions	14.0	-14.0	-0.0	-5.1
Other non-recurring income and expenses	-	-	-	2.1
<b>TOTAL</b>	<b>14.0</b>	<b>-14.0</b>	<b>-0.0</b>	<b>-3.1</b>

Following the application of the new ANC 2022-06 Regulation, income and expenses recorded as non-recurring income are limited to accounting entries of a purely tax nature. The new provisions of the Regulation apply from 2025, with no changes to the 2024 financial statements.

In 2025, no income or expense directly related to a major or extraordinary event, a change in method or an error correction was recorded as non-recurring income.

## NOTE 21 Corporate income tax

### 21.1 Breakdown and changes in corporate income tax

Corporate income tax in 2025 showed net income of €11.9 million, versus a net income of €16.7 million the previous year.

<i>In millions of euros</i>	<b>Before tax</b>	<b>Tax</b>	<b>12/31/2025 After tax</b>	<b>12/31/2024 After tax</b>
Recurring income	308.7	11.9	320.5	453.1
Non-recurring income	-0.0	0.0	-0.0	-1.2
<b>NET INCOME FOR THE YEAR</b>	<b>308.6</b>	<b>11.9</b>	<b>320.5</b>	<b>451.9</b>

### 21.2 Tax credits and reductions

The Company recognized several tax credits for 2025 totaling €20.7 million.

<b>Tax credits and reductions</b> <i>In millions of euros</i>	<b>2025</b>
Research tax credit	15.9
Tax reduction for sponsorship	3.8
Foreign tax credits	0.9
Family tax credit	0.1
<b>TOTAL</b>	<b>20.7</b>

### 21.3 Net income for the year excluding provisions recognized for tax purposes

There were no expenses for accelerated depreciation, amortization and regulated provisions in 2025, compared with €5.1 million in 2024. As a result, these special tax assessments will not generate any tax savings in 2025.

## 21.4 Deferred or latent tax situation

Deferred or latent taxes, resulting from temporary differences between accounting bases and tax bases, are not reflected in the parent company financial statements. The factors likely to lead to reductions and increases in future income tax liability are as follows.

<b>Reductions and increases in future tax liability</b> <i>In millions of euros</i>	<b>12/31/2025</b> <b>Rate 25.83%</b>	<b>12/31/2024</b> <b>Rate 25.83%</b>
Accelerated depreciation, amortization and tax-regulated provisions	21.7	21.7
Depreciation of artwork	0.3	0.3
<b>Total future tax liabilities</b>	<b>22.1</b>	<b>22.0</b>
Non-deductible provisions and expenses	-5.2	-8.2
Unrealized translation differences (gains)	-0.3	-0.1
Reduction of deferred taxes	-7.6 <sup>(a)</sup>	-10.4
<b>Total future tax assets</b>	<b>-13.1</b>	<b>-18.8</b>
<b>NET FUTURE TAX LIABILITY</b>	<b>9.0</b>	<b>3.3</b>

(a) At December 31, 2025, unused corporate sponsorship tax reductions for 2022, 2023, and 2024, which can be carried forward to the next five years, amounted to €7.6 million.

At December 31, 2024, the balance included unused tax reductions for corporate sponsorship from 2022 to 2024 amounting to €7.6 million, and the surplus of donations made in 2020 to charitable causes or organizations, which can be carried forward until 2025 and give rise to a tax reduction after deduction of sponsorship expenses for the year and within the tax ceiling, amounting to €2.8 million.

## NOTE 22 Hedging instruments

### 22.1 Accounting principles

The Company only uses financial instruments for hedging purposes, in order to limit risks stemming from changes in exchange rates and interest rates, whether related to assets and liabilities at the end of the period or to future transactions.

### 22.2 Exchange rate risk

In view of the significant proportion of bioMérieux SA's operations conducted outside the euro zone, its sales, earnings and balance sheet may be impacted by changes in exchange rates between the euro and other currencies. Sales are particularly affected by euro/U.S. dollar exchange rate variations and, more occasionally, by fluctuations in the rate of the euro against other currencies.

bioMérieux SA's current policy is to seek to hedge the impact of exchange rate fluctuations on budgeted net income. It uses hedging instruments, when they are available at a reasonable cost, in order to mitigate risks relating to currency fluctuations. Hedging contracts are purchased to cover transactions included in the budget and not for speculative purposes.

Hedges consist mainly of forward currency sales and purchases (maturing within 18 months at December 31, 2025).

Hedging instruments used are backed against trade and financial receivables and payables.

Unrealized foreign exchange gains and losses on hedging instruments, related to the basis of trading prices at December 31, 2025 are recognized in the balance sheet whenever they are in a hedging relationship with receivables or payables.

Hedges in effect at December 31, 2025 were as follows:

- forward sales of €55.5 million to hedge trade receivables;
- forward sales of €104.6 million to hedge financial receivables;
- forward purchases of €438.0 million to hedge borrowings.

Furthermore, currency hedges were set up to cover the budget positions of the 2026 fiscal year. The net amount of these hedges is €203.8 million.

The market value at December 31, 2025 of all the budget hedges represented an unrealized loss of €1.1 million.

At December 31, 2025, the Company had no hedges covering the earnings of foreign subsidiaries.

The market value of financial hedges at December 31, 2025, represented an unrealized loss of €0.2 million.

The table below shows the currencies in which sales were generated:

In millions of euros	12/31/2025		12/31/2024	
	12 months	%	12 months	%
<b>Euro</b>	<b>1,137.7</b>	<b>67%</b>	<b>1,078.1</b>	<b>66%</b>
<b>Other</b>				
U.S. dollar	141.9	8%	142.5	9%
Singapore Dollar	108.0	6%	129.7	8%
Pound sterling	77.2	5%	70.8	4%
Czech koruna	57.0	3%	54.6	3%
Swiss franc	39.1	2%	41.1	3%
Turkish lira	30.4	2%	25.0	2%
Swedish krona	25.7	2%	26.5	2%
South African rand	18.0	1%	14.7	1%
Mexican peso	12.1	1%	14.0	1%
Russian ruble	-	0%	3.2	0%
Other currencies	47.1	3%	40.6	2%
<b>TOTAL</b>	<b>1,694.2</b>	<b>100%</b>	<b>1,640.7</b>	<b>100%</b>

## 22.3 Interest rate risk

### 22.3.1 Exposure to interest rate risks

A fixed-rate Euro PP bond was issued in June 2020. This bond comprises one seven-year €145 million tranche bearing an annual coupon of 1.50%, and one 10-year €55 million tranche, bearing an annual coupon of 1.902%.

The €45 million property leasing agreement set up in 2015 to finance Campus de l'Etoile is indexed to a variable rate. At December 31, 2025, there was no mechanism set up to back this financing.

### 22.3.2 Hedging instruments

At December 31, 2025, bioMérieux SA had no interest rate hedges.

## NOTE 23 Off-balance sheet commitments

### 23.1 Commitments given

Commitments given In millions of euros	12/31/2025	12/31/2024
Endorsements and guarantees	204.0 <sup>(a)</sup>	202.4
Leasing agreement and rent commitments	24.8	26.1
Research and development	9.4 <sup>(b)</sup>	23.6
Purchase obligations (supply agreements)	27.0	11.6
Sponsorship	4.6 <sup>(c)</sup>	3.5
Other securities	0.1	0.1
<b>TOTAL</b>	<b>269.9</b>	<b>267.3</b>

(a) Related parties for €202.7 million, including a €72 million loan to Shanghai.

(b) Scientific partnership with Biocluster for €8.8 million.

(c) Of which €2.5 million for the Mérieux Foundation.

Lease commitments <i>In millions of euros</i>	Royalties remaining at the end of the fiscal year	Residual purchase price
Land	0.5	
Buildings	10.1	
<b>TOTAL</b>	<b>10.6</b>	<b>-</b>

Lease commitments <i>In millions of euros</i>	Value at contract signing	Initial cost of the asset	Theoretical amortization expenses		Net value
			For the fiscal year	Cumulative	
Land	2.3	2.3	-		2.3
Buildings	42.1	42.1	2.4	22.6	19.5
<b>TOTAL</b>	<b>44.4</b>	<b>44.4</b>	<b>2.4</b>	<b>22.6</b>	<b>21.8</b>

	Royalties paid		Outstanding royalties			Residual purchase price
	For the fiscal year	Cumulative	Less than 1 year	1 to 5 years	In over 5 years	
Land	0.2	1.9	0.2	0.3		
Buildings	3.9	35.3	3.7	6.4		
<b>TOTAL</b>	<b>4.1</b>	<b>37.2</b>	<b>3.9</b>	<b>6.7</b>	<b>-</b>	<b>-</b>

## 23.2 Commitments received

Commitments received <i>In millions of euros</i>	12/31/2025	12/31/2024
Credit facilities with a banking syndicate	600.0	600.0
Other bank guarantees	0.1	1.1
<b>TOTAL</b>	<b>600.1</b>	<b>601.1</b>

## NOTE 24 Related parties

The following are significant transactions between the company and related parties that were subject to regulated agreements.

Name of related party	Nature of relationship with related party	Amount of transactions with related party during the fiscal year	Other information
Institut Mérieux	Holds 58.9% of bioMérieux SA	-12.0	Cost of services and research <sup>(a)</sup>
		0.1	Income from re-invoicing of salaries
Mérieux Foundation	Indirectly holds bioMérieux SA	-2.8	Humanitarian sponsorship
bioMérieux Endowment Fund	Key management personnel in common	-0.1	Humanitarian sponsorship
Mérieux NutriSciences Corporation	Majority owned by Institut Mérieux	0.1	Income from re-invoicing of salaries
Mérieux Université	40% owned by bMsa, 40% by Institut Mérieux, and 20% by Mérieux Nutrisciences	0.1	Income from re-invoicing of salaries

(a) Of which €5.3 million re-invoiced by bioMérieux SA to BioFire Diagnostics and €3.6 million to bioMérieux Inc.

## NOTE 25 Statutory Auditors' fees

The total amount of Statutory Auditors' fees included in the profit & loss statement for the fiscal year, relating to the certification of accounts and other services, is as follows:

<i>In millions of euros</i>	<b>Ernst &amp; Young</b>	<b>Grant Thornton</b>
Fees related to the certification of the financial statements	0.3	0.2
Fees for services other than certification of the financial statements	-	-
<b>TOTAL</b>	<b>0.3</b>	<b>0.2</b>

### 6.2.3 Analysis of the results and other financial information

#### 6.2.3.1 Sales and financial position

##### Sales

During the fiscal year ended December 31, 2025, the Company's net sales amounted to €1,694.2 million, as compared to €1,640.7 million for the previous year, representing a year-on-year increase of €53.7 (3.3%).

The change in sales is due to the growth in export sales of €20.7 million (10.2%), mainly attributable to the BioFire ranges for €10.9 million, sales to subsidiaries of €3.3 million (0.4%), offset by a decline in domestic sales of €4.7 million (2%), mainly due to the decline in the BioFire ranges. Rebilling of subsidiaries for services increased by €33.5 million, mainly due to management and IT services.

##### Operating income

Operating income increased by €22.9 million, from a loss of €13.8 million in 2024 to a gain of €9.1 million at December 31, 2025.

The change in operating income is mainly due to the growth in added value generated by sales of €18 million. The application of the new ANC 2022-06 regulation aimed at modernizing financial statements had a negative impact of €3.5 million on operating income.

##### Net financial income

Financial income amounted to €299.6 million at December 31, 2025, compared with €452 million the previous year, down €152.4 million.

This change was largely due to a €130.4 million decrease in income from equity investments, €125.7 million of which came from bioMérieux Inc.

##### Recurring income

Net income before non-recurring items and tax totaled €308.7 million at December 31, 2025, compared with €438.3 million one year earlier.

##### Non-recurring income

There was no non-recurring income at December 31, 2025, compared with a loss of €3.1 million at December 31, 2024. This change stems from the application of the new ANC 2022-06 Regulation in 2025. Non-recurring income is now limited to items resulting from a major and extraordinary event.

##### Employee profit-sharing

As in 2024, no profit-sharing was recorded in fiscal year 2025.

##### Income tax and tax credits

Income tax amounted to net income of €11.9 million at December 31, 2025, compared with income of €16.7 million at December 31, 2024.

For the 2025 fiscal year, the Company generated tax income of €27.9 million, representing a corporate income tax expense of €8.1 million (compared with €1.9 million at December 31, 2024). Tax credits recognized in 2025 totaled €20.7 million (mainly research tax credit), compared with €20.3 million in 2024.

##### Net income

Net income amounted to €320.5 million, versus €451.9 million the previous fiscal year, or a decrease of €131.4 million. It represented 18.9% of sales, as compared to 27.5% at December 31, 2024.

##### Capital expenditure

For 2025 fiscal year, investments in intangible assets amounted to €129.7 million, mainly relating to the acquisition of SpinChip's intellectual property rights for €105.3 million and those relating to Day Zero Diagnostics' sequencing for €18.1 million.

Investments in property, plant, and equipment, amounting to €101.1 million in 2025, mainly related to investments for the production of reagents at the La Balme site for €32.6 million, the construction of a new industrial building for molecular biology in Marcy l'Étoile for €11.8 million, the construction of a research and development building in Grenoble for €9.3 million, and investments in instruments for customers or for internal use amounting to €9.2 million.

Non-current financial assets increased by €193.9 million in gross value over the 2025 fiscal year, mainly due to the acquisition of SpinChip Diagnostics ASA for €112.3 million and several capital increases in subsidiaries for a total amount of €77.9 million.

### 6.2.3.2 Appropriation of net income and non-deductible expenses

Shareholders will be invited to appropriate distributable net income for the fiscal year ended December 31, 2025, totaling €320,480,242.95 and consisting of €635,861,297.80 in net income and €956,341,540.75 in retained earnings, as follows:

- €635,861,297.80 to be transferred to the General Reserve account, increasing the balance from €905,000,000.28 to €1,540,861,298.08;
- a sum of €0 will be wired to the Special Sponsorship Reserve account which will remain at €1,020,052.58;
- €115,993,995.60 to be distributed as dividends, representing a dividend of €0.98 for each of the 118,361,220 shares comprising the share capital; to be paid on June 11, 2026;
- the balance of €204,486,247.35 is to be paid to "Retained earnings."

In accordance with Article L. 225-210 of the French Commercial Code (Code de commerce), the Company will not receive any dividends on treasury shares held at the ex-dividend date. The corresponding dividend amount will be allocated to "Retained earnings."

Under current French tax legislation, the dividends distributed to individuals domiciled in France for tax purposes are taxed in two phases:

- upon payment, the gross amount is subject to a non-discharging levy (French acronym PFNL) of 12.8% for income tax (Article 117

quater of the French Tax Code [Code général des impôts]) and social security withholdings of 17.2%. Low-income taxpayers may request exemption from the PFNL;

- the following year, they are subject:
  - to tax at the flat rate of 12.8% (single flat-rate levy),
  - or, optionally, to the progressive income tax schedule. In that case, an abatement of 40% applies (Article 158, 3 2° of the French Tax Code).

The PFNL of 12.8%, deducted during the payment year, is deducted in this case from income tax. The excess, if any, is refunded.

The dividends paid for each of the past three fiscal years are presented in § 7.6.

#### Non-tax-deductible expenses

The financial statements of the previous fiscal year include non-tax-deductible expenses as provided for in Articles 223 quater and 223 quinquies of the French Tax Code (*Code général des impôts*) amounting to €1,001,838. These represent the non-deductible portion of rental payments and depreciation charges for vehicles leased and purchased by bioMérieux SA. Income tax at the base rate paid in this respect amounted to €250,459.50.

## 6.2.3.3 Five-year financial summary (Article R. 225-102 of the French Commercial Code)

	Fiscal year ended 12/31/2025	Fiscal year ended 12/31/2024	Fiscal year ended 12/31/2023	Fiscal year ended 12/31/2022	Fiscal year ended 12/31/2021
<b>I. SHARE CAPITAL AT YEAR-END</b>					
Share capital (in euros)	12,029,370	12,029,370	12,029,370	12,029,370	12,029,370
Number of existing ordinary shares	118,361,220	118,361,220	118,361,220	118,361,220	118,361,220
Number of preferred shares (without voting rights) outstanding	0	0	0	0	0
Maximum number of potential shares to be issued	0	0	0	0	0
By conversion of bonds	0	0	0	0	0
By exercise of subscription rights	0	0	0	0	0
<b>II. TRANSACTIONS AND NET INCOME FOR THE FISCAL YEAR (IN EUROS)</b>					
Pre-tax sales	1,694,212,842	1,640,669,144	1,546,836,131	1,463,637,568	1,456,769,994
Income before tax, employee profit- sharing, depreciation, amortization and provisions	401,139,175	525,254,812	389,497,738	97,769,544	290,693,609
Income tax <sup>(a)</sup>	-11,865,345	-16,703,792	-15,053,148	-19,034,981	13,129,696
Employee profit-sharing for the fiscal year	0	0	0	2,013,060	2,031,081
Income after tax, employee profit- sharing, depreciation, amortization and provisions	320,480,243	451,898,979	279,345,022	86,966,342	205,625,092
Dividends paid <sup>(b)</sup>	115,993,996	106,525,098	100,607,037	100,607,037	100,607,037
Special dividend paid from the general reserve	0	0	0	0	0
<b>III. EARNINGS PER SHARE (IN EUROS)</b>					
Income after tax and employee profit- sharing, but before depreciation, amortization and provisions	3.49	4.58	3.42	0.97	2.33
Income after tax, employee profit- sharing, depreciation, amortization and provisions	2.99	3.82	2.36	0.73	1.73
Dividend per share	0.98	0.90	0.85	0.85	0.85
<b>IV. EMPLOYEE DATA</b>					
Average headcount during the fiscal year <sup>(c)</sup>	4,115	4,036	4,048	3,913	3,798
Total annual payroll for the fiscal year (in euros)	305,687,849	303,743,511	283,171,106	268,158,102	245,899,960
Total employee benefits paid during the fiscal year (social security, charities) (in euros)	149,391,391	136,268,027	124,700,151	115,313,012	111,759,753

(a) The negative amounts signify tax income.

(b) Subject to the non-payment of dividends on treasury shares held on the ex-dividend date.

(c) Excluding interns, apprentices, professional training contracts and international work experience volunteers (VIE). 2024 data changed from that previously published in order to homogenize the headcount.

### 6.2.3.4 Information on payment periods

#### Trade payables at December 31, 2025 by due date

In accordance with Article D. 441-4 of the French Commercial Code (Code de commerce), invoices received and not paid at December 31, 2025 that are in arrears break down as follows:

#### SUPPLIER INVOICES (NON-GROUP)

##### Invoices received that have not been settled on the closing date of the fiscal year and are in arrears

	0 days (as a reference)	1 to 30 days	31 to 60 days	61 to 90 days	91 days or more	Total (1 day or more)
<b>(A) LATE PAYMENT RANGES</b>						
Number of invoices concerned	61	13	37	12	55	117
Total amount of invoices concerned (inclusive of tax)	1,556,947	362,791	269,059	62,851	517,917	1,212,618
Percentage of total purchases for the fiscal year	0.26%	0.06%	0.05%	0.01%	0.10%	0.22%
<b>(B) INVOICES EXCLUDED FROM (A) RELATING TO DISPUTED DEBTS OR UNRECOGNIZED DEBTS</b>						
Number of invoices excluded			234			
Total amount of invoices excluded (inclusive of tax)			2,988,810			
<b>(C) REFERENCE PAYMENT PERIOD USED (CONTRACTUAL OR STATUTORY PERIOD – ARTICLE L. 441-6 OR ARTICLE L. 443-1 OF THE FRENCH COMMERCIAL CODE)</b>						
Payment schedules used in calculating late payments	Contractual period: 0 to 45 days from the end of the month, according to the contract					

#### SUPPLIER INVOICES (NON-GROUP AND GROUP)

##### Invoices received that have not been settled on the closing date of the fiscal year and are in arrears

	0 days (as a reference)	1 to 30 days	31 to 60 days	61 to 90 days	91 days or more	Total (1 day or more)
<b>(A) LATE PAYMENT RANGES</b>						
Number of invoices concerned	61	22	41	16	69	148
Total amount of invoices concerned (inclusive of tax)	1,556,947	4,231,645	993,450	2,616,318	3,360,536	11,201,950
Percentage of total purchases for the fiscal year	0.12%	0.37%	0.08%	0.23%	0.29%	0.98%
<b>(B) INVOICES EXCLUDED FROM (A) RELATING TO DISPUTED DEBTS OR UNRECOGNIZED DEBTS</b>						
Number of invoices excluded			240			
Total amount of invoices excluded (inclusive of tax)			3,575,859			
<b>(C) REFERENCE PAYMENT PERIOD USED (CONTRACTUAL OR STATUTORY PERIOD – ARTICLE L. 441-6 OR ARTICLE L. 443-1 OF THE FRENCH COMMERCIAL CODE)</b>						
Payment schedules used in calculating late payments	Contractual period: 0 to 60 days from the end of the month, according to the contract for suppliers					

**Trade receivables at December 31, 2025 by due date**

In accordance with Article D. 441-4 of the French Commercial Code (Code de commerce), invoices issued and not paid at December 31, 2025 that are in arrears break down as follows:

**CLIENT INVOICES (NON-GROUP)****Invoices issued that have not been settled on the closing date of the fiscal year and are in arrears**

	<b>0 days (as a reference)</b>	<b>1 to 30 days</b>	<b>31 to 60 days</b>	<b>61 to 90 days</b>	<b>91 days or more</b>	<b>Total (1 day or more)</b>
<b>(A) LATE PAYMENT RANGES</b>						
Number of invoices concerned	948	1,647	976	661	1,818	5,102
Total amount of invoices concerned (inclusive of tax)	4,951,458	4,374,116	2,555,887	1,978,996	1,692,399	10,601,399
Percentage of sales for the fiscal year	0.97%	0.86%	0.50%	0.39%	0.33%	2.08%
<b>(B) INVOICES EXCLUDED FROM (A) RELATING TO DISPUTED OR UNRECOGNIZED RECEIVABLES <sup>(a)</sup></b>						
Number of invoices excluded			2,124			
Total amount of invoices excluded (inclusive of tax)			17,457,694			
<b>(C) REFERENCE PAYMENT PERIODS USED</b>						
Payment schedules used in calculating late payments	Contractual periods: France: between 30 days end of month and 60 days net Export: between 30 days net and 120 days net					

(a) Including doubtful debts

**CLIENT INVOICES (NON-GROUP AND GROUP)****Invoices issued that have not been settled on the closing date of the fiscal year and are in arrears**

	<b>0 days (as a reference)</b>	<b>1 to 30 days</b>	<b>31 to 60 days</b>	<b>61 to 90 days</b>	<b>91 days or more</b>	<b>Total (1 day or more)</b>
<b>(A) LATE PAYMENT RANGES</b>						
Number of invoices concerned	952	1,980	1,129	758	1,998	5,865
Total amount of invoices concerned (inclusive of tax)	4,914,667	14,558,842	6,282,106	4,888,927	4,764,894	30,494,770
Percentage of sales for the fiscal year	0.28%	0.83%	0.36%	0.28%	0.27%	1.73%
<b>(B) INVOICES EXCLUDED FROM (A) RELATING TO DISPUTED OR UNRECOGNIZED RECEIVABLES <sup>(a)</sup></b>						
Number of invoices excluded			2,124			
Total amount of invoices excluded (inclusive of tax)			17,457,694			
<b>(C) REFERENCE PAYMENT PERIODS USED (CONTRACTUAL OR STATUTORY PERIOD – ARTICLE L. 441-6 OR ARTICLE L. 443-1 OF THE FRENCH COMMERCIAL CODE)</b>						
Payment schedules used in calculating late payments	Contractual periods: France: between 30 days end of month and 60 days net Export: between 30 days net and 210 days net					

(a) Including doubtful debts

## 6.2.4 Statutory Auditors' report on the parent company annual financial statements

*This is a free translation into English of the Statutory Auditors' report issued in French and is provided solely for the convenience of English speaking readers. The Statutory Auditors' report includes information specifically required by French law in such reports, whether modified or not. This information is presented below the opinion on the financial statements and includes an explanatory paragraph discussing the Auditors' assessments of certain significant accounting and auditing matters. These assessments were considered for the purpose of issuing an audit opinion on the financial statements taken as a whole and not to provide separate assurance on individual account captions or on information taken outside of the financial statements. This report should be read in conjunction with, and construed in accordance with, French law and professional auditing standards applicable in France.*

To the bioMérieux Annual General Meeting,

### Opinion

In performing the duty entrusted to us by your Annual General Meetings, we conducted an audit of the annual financial statements of bioMérieux for the fiscal year ended December 31, 2025, as appended to this report.

We certify that with regard to French accounting rules and principles, the annual financial statements are reliable and faithfully reflect the operating results of the previous fiscal year, as well as the financial position and assets of the Company at the close of the said fiscal year.

The opinion expressed above is consistent with the contents of our report to the Audit Committee.

### Basis for opinion

#### Audit Standard

We conducted our audit according to generally accepted professional standards in France. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Our responsibilities by virtue of these standards are stated in the section "Responsibilities of the Statutory Auditors relating to the audit of the annual financial statements" of this report.

#### Independence

We have conducted our audit in accordance with the rules of independence as set out in the French Commercial Code and in the French Code of Ethics for Statutory Auditors, over the period between January 1, 2025 to the date of issue of our report, and in particular we have not provided any services prohibited by Article 5(1) of EU Regulation No. 537/2014.

### Note

Without calling into question the opinion expressed above, we would like to point out "Note 1. General accounting principles" in the notes to the annual financial statements, which explain the change in accounting method resulting from the application of ANC Regulation No. 2022-06.

### Justification for our assessments – Key points of the audit

Pursuant to the provisions of Articles L. 821-53 and R. 821-180 of the French Commercial Code relating to the justification of our assessments, we draw your attention to the key points of the audit relating to risks of material misstatements which, according to our professional judgment, were the most significant for the audit of the annual financial statements for the fiscal year, plus the answers we have provided to control these risks.

Our assessments on these matters are part of the audit approach of the annual financial statements taken as a whole and the formation of our opinion expressed above. We do not express an opinion on the elements of these annual financial statements taken separately.

### Assessment of equity investments

#### Risk identified

Equity investments were recorded in the balance sheet in the net amount of €1,191.4 million at December 31, 2025, and represented 33% of total balance sheet.

They are recognized at their acquisition cost and impaired whenever their value in use falls below their acquisition cost. As stated in Note 4.4 of the notes to the annual financial statements, the value in use is estimated by the management either:

- by taking into account the net book value of the subsidiary at the balance sheet date, potentially adjusted to reflect the value of any unrecognized identifiable assets (particularly real estate or technologies);
- given the specific nature of certain investments, based on discounted future cash flows or on observable market financial inputs.

The estimation of the value in use of these securities requires that the management exercise its judgment in selecting the elements to be considered depending on the investments concerned (cash flow, discount rate, etc.).

As such and given the importance of these assets on the balance sheet, we considered the assessment of equity investments to be a key audit matter.

#### Our response

We analyzed the assessment method used and the figures on which it is based.

For assessments based on historic elements, where appropriate adjusted to reflect the value of any unrecognized identifiable assets, our work consisted primarily in examining the consistency of the net assets used with the accounts of the entities, and in checking whether any adjustments made were supported by meaningful documentation.

For assessments based on provisional data, our work consisted primarily in:

- assessing the consistency of cash flow and operating forecasts for the activities of the entities concerned and with the forecast data presented by senior management as part of the budgeting process;
- analyzing the consistency of the assumptions used with the economic environment at the closing and preparation dates of the financial statements;
- carrying out our own assessment as regards the discount rate to be used for the discounting of cash flows and comparing it with that of your company.

## Specific verification

In accordance with the professional standards applicable in France, we have also undertaken the specific verifications required by law and by regulations.

### Information given in the management report and in the other documents sent to shareholders about the Company's financial position and annual financial statements

We have no matters to report as to the fair presentation and the consistency with the annual financial statements of the information given in the management report of the Board of Directors, and in the documents addressed to the shareholders with respect to the financial position and the annual financial statements.

We hereby certify the fairness and the consistency with the annual financial statements of the information regarding payment periods described in Article D. 441-6 of the French Commercial Code.

### Report on corporate governance

We certify that the Board of Directors' report on corporate governance contains the information required by Articles L. 225-37-4, L. 22-10-10 and L. 22-10-9 of the French Commercial Code.

Concerning the information disclosed in accordance with the requirements of Article L. 22-10-9 of the French Commercial Code, relating to compensation and benefits received by corporate officers and any other commitments made in their favor, we have verified its consistency with the financial statements, or with the underlying information used to prepare these financial statements and, where applicable, with the information obtained by your Company from companies controlled by it and included in the scope of consolidation. Based on this work, we attest to the accuracy and fair presentation of this information.

Concerning the information on the elements that your Company considered likely to have an impact in the event of a takeover bid with stock purchase or exchange, provided pursuant to the provisions of Article L. 22-10-11 of the French Commercial Code, we verified their compliance with the documents from which they were created and that were forwarded to us. On the basis of these verifications, we have no observation to make with regard to this information.

### Other information

As required by law, we are satisfied that the various disclosures about equity investments and takeovers, and the identity of those who hold equity and voting rights, have been communicated to you in the management report.

## Other verifications or information required by laws and regulations

### Format of the annual financial statements to be included in the annual financial report

In accordance with the professional standard on the due diligence of statutory auditors in relation to the annual and consolidated financial statements presented in accordance with the single European electronic reporting format, we have also verified compliance with this format, as defined by European Delegated Regulation No. 2019/815 of December 17, 2018, as presented in the annual financial statements to be included in the annual financial report referred to in Article L. 451-1-2, I of the French Monetary and Financial Code. These have been prepared under the responsibility of the Chief Executive Officer.

Based on our work, we conclude that the presentation of the annual financial statements for inclusion in the annual financial report complies, in all material respects, with the single European electronic reporting format.

It is not our responsibility to verify that the annual financial statements that your company will include in the annual financial report filed with the AMF correspond to those we have audited.

### Appointment of Statutory Auditors

We were appointed Statutory Auditors of bioMérieux by your Annual General Meeting of May 30, 2017 for GRANT THORNTON and May 30, 2012 for ERNST & YOUNG et Autres.

At December 31, 2025, GRANT THORNTON was in the ninth continuous year of its audit engagement, while ERNST & YOUNG et Autres was in the 14th year.

## Responsibilities of senior management and the persons constituting corporate governance for the annual financial statements

Senior management is responsible for the preparation of annual financial statements that present a true view in compliance with French accounting rules and principles, together with the implementation of the internal control that it deems relevant to the preparation of annual financial statements that are free from material misstatement, whether due to fraud or error.

When preparing the annual financial statements, senior management is responsible for assessing the Company's ability to continue as a going concern, to present in these financial statements, if necessary, information concerning the continuity of the Company's operations and to apply the accounting policy of going concern, unless there are plans to unwind the Company or discontinue the business.

The Audit Committee is responsible for monitoring the financial reporting preparation process and the effectiveness of internal control and risk management systems and, if necessary, the Internal Audit Department with respect to procedures relating to preparation and treatment of financial and accounting information.

The annual financial statements have been approved by the Board of Directors.

## Responsibilities of the Statutory Auditors relating to the audit of the annual financial statements

### Audit objective and procedure

It is our duty to draw up a report on the annual financial statements. Our objective is to obtain reasonable assurance that the annual financial statements, taken as a whole, are free from material misstatement. Reasonable assurance corresponds to a high level of assurance, without however guaranteeing that an audit conducted in accordance with professional standards will systematically detect any material misstatement. Misstatements may arise from fraud or result from errors and are considered as material when it can be reasonably expected that, taken singly or together, they can influence the economic decisions that users of the financial statements take based thereon.

As stated in Article L. 821-55 of the French Commercial Code, our engagement to certify the financial statements does not consist in guaranteeing the viability or quality of management of your Company.

Within the framework of an audit conducted in compliance with professional standards applicable in France, the statutory Auditor exercises his professional judgment throughout the audit. Furthermore:

- the statutory auditor identifies and assesses the risks whereby the annual financial statements may contain material misstatements, whether from fraud or errors; defines and implements audit procedures in view of those risks; and collects the elements they consider sufficient and appropriate on which to base their opinion. The risk of not detecting a material misstatement arising from fraud is higher than the risk of a material misstatement resulting from error, because fraud may imply collusion, falsification, voluntary omissions, false declarations or the circumvention of internal control;
- the statutory auditor reviews the relevant internal control for the audit in order to define the appropriate audit procedures for the circumstances and not to express an opinion on the effectiveness of internal control;
- he assesses the appropriateness of the accounting methods used and the reasonable nature of the accounting estimates made by the management, as well as information concerning these methods provided in the annual financial statements;
- he assesses the appropriateness of the application by the management of the going concern concept and, according to the elements collected, whether or not there is a material uncertainty linked to events or circumstances likely to compromise the Company's ability to continue as a going concern. This assessment is based on the information collected until the date of his report. It is however pointed out that subsequent circumstances or events could jeopardize continuity as a going concern. If he concludes that there is a material uncertainty, the statutory auditor draws the attention of the readers of the report to the information provided in the annual financial statements about such uncertainty, or if this information is not provided or is not relevant, he issues a certification with reservations or a refusal to certify;
- he assesses the overall presentation of the annual financial statements and whether these reflect underlying operations and events, so as to give a true view.

### Report to the Audit Committee

We submit a report to the Audit Committee that presents, in particular, the scope of the audit and the work schedule implemented as well as the conclusions of our audit. Our audit also informs the Audit Committee of any material weaknesses of internal control that we have identified with respect to the procedures relating to the preparation and treatment of financial and accounting information.

The points mentioned in the report to the Audit Committee include the risks of material misstatements that we consider to have been the most important for the audit of the annual financial statements of the fiscal year, which therefore constitute the key points of the audit, which it is our duty to describe in this report.

We also submit to the Audit Committee the declaration provided for in Article 6 of EU Regulation No. 537/2014 confirming our independence, within the meaning of the rules applicable in France as set out in Articles L. 821-27 to L. 821-34 of the French Commercial Code and in the Statutory Auditors' Professional Code of Ethics. If necessary, we will meet the Audit Committee to discuss the risks that threaten our independence and the safeguard measures applied.

Lyon, March 13, 2026

The Statutory Auditors

GRANT THORNTON

*French member of Grant Thornton International*

Jean Morier

ERNST & YOUNG et Autres

Sylvain Lauria